%PDF-1.4%âãÏÓ
62 0 obj
<</Metadata 64 0 R/PageLabels 8 0 R/Pages 57 0 R/Type/Catalog>>
endobj
64 0 obj
<</Length 1662/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 4.2.1-c043 52.389687, 2009/06/02-13:20:35        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/">
         <xmp:CreateDate>2013-02-05T16:00:19Z</xmp:CreateDate>
         <xmp:CreatorTool>QuarkXPress(tm) 6.5</xmp:CreatorTool>
         <xmp:ModifyDate>2015-05-25T05:40:51-07:00</xmp:ModifyDate>
         <xmp:MetadataDate>2015-05-25T05:40:51-07:00</xmp:MetadataDate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/">
         <pdf:Producer>QuarkXPress(tm) 6.5</pdf:Producer>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">Layout 1</rdf:li>
            </rdf:Alt>
         </dc:title>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <pdfx:XPressPrivate>%%DocumentProcessColors: Black&#xA;%%EndComments</pdfx:XPressPrivate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <xmpMM:DocumentID>uuid:687fbf0f-1dd2-11b2-0a00-6708279d8f00</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:687fbf14-1dd2-11b2-0a00-14f600000000</xmpMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>
endstream
endobj
8 0 obj
<</Nums[0<</S/D>>]>>
endobj
57 0 obj
<</Count 4/Kids[58 0 R 59 0 R 60 0 R 61 0 R]/Type/Pages>>
endobj
58 0 obj
<</Annots 65 0 R/Contents 66 0 R/MediaBox[0 0 594 783]/Parent 57 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 67 0 R/GS2 68 0 R>>/Font<</T1_0 12 0 R/T1_1 16 0 R/T1_10 69 0 R/T1_2 20 0 R/T1_3 24 0 R/T1_4 28 0 R/T1_5 32 0 R/T1_6 36 0 R/T1_7 40 0 R/T1_8 44 0 R/T1_9 48 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
59 0 obj
<</Annots 70 0 R/Contents 71 0 R/MediaBox[0 0 594 783]/Parent 57 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 72 0 R/GS2 73 0 R>>/Font<</T1_0 16 0 R/T1_1 20 0 R/T1_2 36 0 R/T1_3 52 0 R/T1_4 32 0 R/T1_5 28 0 R/T1_6 56 0 R/T1_7 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
60 0 obj
<</Annots 74 0 R/Contents 75 0 R/MediaBox[0 0 594 783]/Parent 57 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 76 0 R/GS2 77 0 R>>/Font<</T1_0 16 0 R/T1_1 20 0 R/T1_2 36 0 R/T1_3 12 0 R/T1_4 40 0 R/T1_5 56 0 R/T1_6 28 0 R/T1_7 32 0 R/T1_8 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
61 0 obj
<</Annots 78 0 R/Contents 79 0 R/MediaBox[0 0 594 783]/Parent 57 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 80 0 R/GS2 81 0 R>>/Font<</T1_0 16 0 R/T1_1 20 0 R/T1_2 32 0 R/T1_3 28 0 R/T1_4 56 0 R/T1_5 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
78 0 obj
[82 0 R]
endobj
79 0 obj
<</Length 10129>>stream
1 g
/GS0 gs
0 783 0 0 re
f
0 0 0 0 k
/GS1 gs
50.5 312.558 493 420.635 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.006 Tc 0.006 Tw 8 0 0 8 50.5 727.7228 Tm
[(19.)-494 (Seeman P)110 (. An update of fast-)-75 (of)20 (f dopamine D)]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 5 0 0 5 206.5267 726.0727 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
-0.006 Tc 0.006 Tw 8 0 0 8 210.996 727.7228 Tm
(atypical antipsychotics.)Tj
-0.02499 Tc 0.013 Tw -18.3745 -1.25 Td
[(Am J Psychiatry 2010;162:1984)-75 (-5.)]TJ
-0.01199 Tc 0.01199 Tw -1.6875 -1.375 Td
[(20.)-488 (Stahl SM. \322Hit-and-run\323 actions at dopamine receptors, part 1: mec\ha)-1 (-)]TJ
-0.03999 Tc 0.013 Tw 1.6875 -1.25 Td
[(nism of action of atypical antipsychotics. J Clin Psychiatry 2001;19:165\)-25 (-)-25 (8. )]TJ
-0.017 Tc 0.017 Tw -1.6875 -1.375 Td
[(21.)-483 (Li EC, Esterly JS, Pohl S, Scott SD, McBride BF)80 (. Drug-induced QT)90 (-)1 (i)1 (n)1 (-)]TJ
0 Tc 0.133 Tw 1.6875 -1.25 Td
[(terval prolongation: considerations for clinicians. Phar)-25 (macotherapy)]TJ
-0.02499 Tc 0 Tw 0 -1.25 TD
[(2010;30:684)-75 (-701.)]TJ
-0.00999 Tc 0.00999 Tw -1.6875 -1.375 Td
[(22.)-490 (Gupta A, Lawrence A)110 (T)76 (, Krishnan K, Kavinsky CJ, T)35 (rohman RG. Cur-)]TJ
-0.01199 Tc 0.01199 Tw 1.6875 -1.25 Td
(rent concepts in the mechanisms and management of drug-induced QT)Tj
-0.02499 Tc 0.013 Tw T*
[(prolongation and torsades de pointes. Am Heart J 2007;153:891)50 (-9.)]TJ
-0.021 Tc 0.021 Tw -1.6875 -1.375 Td
[(23.)-479 (Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
[(fluoroquinolone therapy)65 (. Int J Antimicrob Agents 2007;29:374)-75 (-9.)]TJ
-0.005 Tc 0.005 Tw -1.6875 -1.375 Td
[(24.)-495 (V)109 (eiweg WV)130 (, W)80 (ood MA, Fer)-25 (nandez A, Beatty-Brooks M, Hasnain M,)]TJ
-0.011 Tc 0.011 Tw 1.6875 -1.25 Td
(Pangurangi AK. Proarrhythmic risk with antipsychotic and antidepres-)Tj
-0.02499 Tc 0.013 Tw T*
[(sant drugs: implications in the elderly)65 (. Drugs Aging 2009;26:997-1012.)]TJ
-0.005 Tc 0.005 Tw -1.6875 -1.375 Td
[(25.)-495 (M)1 (e)1 (y)1 (e)1 (r)21 (-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ.)]TJ
-0.02 Tc 0.02 Tw 1.6875 -1.25 Td
[(The FDA extended war)-25 (ning for intravenous haloperidol and torsades de)]TJ
-0.02499 Tc 0.013 Tw T*
[(pointes: how should institutions respond? J Hosp Med 2010;5:E8)-25 (-16.)]TJ
T*
(doi: 10.1002/jhm.691)Tj
0.02299 Tw -1.6875 -1.375 Td
[(26.)-475 (Harrigan EP)110 (, Miceli JJ, Anziano R, et al. A randomized evaluation of the)]TJ
0.002 Tw 1.6875 -1.25 Td
[(ef)20 (fects of six antipsychotic agents on QT)70 (c, in the absence and presence of)]TJ
0.013 Tw T*
[(metabolic inhibition. J Clin Psychophar)-25 (macol 2004;24:62-9.)]TJ
0 Tc 0.088 Tw -1.6875 -1.375 Td
[(27.)-500 (Psychophar)-25 (macological Drugs Advisory Committee. 19 July)65 (, 2000.)]TJ
0.05499 Tw 1.6875 -1.25 Td
(Briefing document for Zeldox capsules \(ziprasidone hydrochloride\).)Tj
-0.024 Tc 0.024 Tw T*
[(www)65 (.fda.gov/ohr)-25 (ms/dockets/ac/00/backgrd/3619b1.htm  \(accessed 2012)]TJ
-0.02499 Tc 0.013 Tw T*
(Jun 1\).)Tj
0 Tc 0.20399 Tw -1.6875 -1.375 Td
[(28.)-500 (Product infor)-25 (mation. Seroquel \(quetiapine\). W)40 (ilmington, DE: As-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
(traZeneca, July 201)Tj
0 Tw 7.37224 0 Td
(1.)Tj
-0.009 Tc -9.05974 -1.375 Td
(29.)Tj
0 Tc 1.71479 0 Td
(T)Tj
-0.009 Tc 0.009 Tw 0.53196 0 Td
(an HH, Hoppe J, Heard K. A systematic review of cardiovascular ef)Tj
0 Tc 26.73281 0 Td
(-)Tj
-0.02499 Tc 0.024 Tw -27.29206 -1.25001 Td
[(fects after atypical antipsychotic medication overdose. Am J Emer)20 (g Med)]TJ
0.013 Tw T*
(2009;27:607-16. doi: 10.1016/j.ajem.2008.04.020)Tj
-0.024 Tc 0 Tw -1.6875 -1.375 Td
(30.)Tj
0.024 Tw 1.65528 0 Td
(Lo B, Pizon A. Delayed presentation of an aripiprazole overdose \(letter\\).)Tj
-0.02499 Tc 0.013 Tw 0.03222 -1.25001 Td
[(Clin T)70 (oxicol \(Phila\) 2008;46:348)-25 (-9. doi: 10.1080/15563650701704859)]TJ
0 Tw -1.6875 -1.375 Td
(31.)Tj
0.002 Tw 1.64999 0 Td
[(Suzuki Y)130 (, Or)-25 (no S, Fukui N, et al. Dose-)-75 (dependent increase in the QT)70 (c in-)]TJ
-0.021 Tc 0.021 Tw 0.03751 -1.25001 Td
(terval in aripiprazole treatment after risperidone \(letter\). Prog Neur\opsy-)Tj
-0.02499 Tc 0 Tw T*
(chophar)Tj
0.013 Tw 3.07035 0 Td
(macol Biol Psychiatry 201)Tj
0 Tw 10.01428 0 Td
[(1;35:643)-25 (-)-125 (4. )]TJ
0.013 Tw -13.08463 -1.25001 Td
(doi: 10.1016/j.pnpbp.2010.10.024)Tj
-0.022 Tc 0.022 Tw -1.6875 -1.375 Td
[(32.)-478 (Leo R, Razzini C, Di Lorenzo G, et al. Asymptomatic QT)70 (c prolongation)]TJ
-0.006 Tc 0.006 Tw 1.6875 -1.25 Td
(during coadministration of aripiprazole and haloperidol \(letter\). J Cl\in)Tj
-0.02499 Tc 0.013 Tw T*
[(Psychiatry 2008;62:327-)-25 (8. )]TJ
0.002 Tw 30.625 50.375 Td
[(33.)-475 (LoV)110 (ecchio F)80 (, W)80 (atts D, W)40 (inchell J. One-year experience with aripiprazole)]TJ
0.013 Tw 1.6875 -1.25 Td
[(exposures \(letter\). Am J Emer)20 (g Med 2005;23:585)-25 (-)-75 (6.)]TJ
-0.01601 Tc 0.01601 Tw -1.6875 -1.375 Td
[(34.)-484 (Carstairs SD, W)40 (illiams SR. Overdose of aripiprazole, a new type of an-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
[(tipsychotic. J Emer)20 (g Med 2005;28:31)35 (1)50 (-)-25 (3. )]TJ
T*
[(doi: 10.1016/j.jemer)20 (gmed.2004.09.013)]TJ
-0.035 Tc 0.02 Tw -1.6875 -1.375 Td
[(3)-15 (5)-15 (.)-496 (G)1 (u)-1 (l)1 (isano M, Cal\223 PV)130 (, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardio)-1 (-)]TJ
-0.03999 Tc 0.015 Tw 1.6875 -1.25 Td
[(vascular safety of aripiprazole and pimozide in young patients with T)70 (ourette)]TJ
0.013 Tw T*
[(syndrome. Neurol Sci 201)35 (1;32:1213)-25 (-7. doi: 10.1007/s10072-)-100 (01)35 (1)50 (-)-99 (0678)-25 (-1)]TJ
-0.01401 Tc 0.01401 Tw -1.6875 -1.375 Td
[(36.)-486 (Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment)]TJ
-0.02499 Tc 0.019 Tw 1.6875 -1.25 Td
[(of schizophrenia: safety and tolerability in short-ter)-25 (m, placebo-controlled)]TJ
0.013 Tw T*
[(trials. Schizophr Res 2003;61:123)-25 (-)-25 (36.)]TJ
-0.011 Tc 0.00999 Tw -1.6875 -1.375 Td
[(3)-1 (7)-1 (.)-491 (B)1 (e)-1 (r)-25 (man RM, Marcus RN, Swanink R, et al. The ef)20 (ficacy and safety of)]TJ
-0.019 Tc 0.019 Tw 1.6875 -1.25 Td
(aripiprazole as adjunctive therapy in major depressive disorder: a multi\-)Tj
-0.013 Tc 0.013 Tw T*
[(c)1 (e)1 (n)1 (t)1 (e)1 (r)41 (, randomized, double-blind, placebo-controlled study)65 (. J Clin Psy-)]TJ
-0.02499 Tc T*
[(chiatry 2007;68:843)-25 (-53.)]TJ
-0.01401 Tc 0.01401 Tw -1.6875 -1.375 Td
[(38.)-486 (T)35 (ran-Johnson TK, Sack DA, Marcus RN, Auby P)110 (, McQuade RD, Oren)]TJ
-0.005 Tc 0.005 Tw 1.6875 -1.25 Td
[(DA. Ef)20 (ficacy and safety of intramuscular aripiprazole in patients with)]TJ
-0.008 Tc 0.008 Tw T*
(acute agitation: a randomized, double-blind, placebo-controlled trial. J\)Tj
-0.02499 Tc 0.013 Tw T*
[(Clin Psychiatry 2007;68:1)35 (1)35 (1)50 (-9. )]TJ
-0.035 Tc -1.6875 -1.375 Td
[(3)-10 (9)-10 (.)-485 (Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the prob\-)]TJ
1.6875 -1.25 Td
[(ability of adverse drug reactions. Clin Phar)-25 (macol Ther 1981;30:239)-25 (-)-125 (45.)]TJ
0 Tc 0.05099 Tw -1.6875 -1.375 Td
[(40.)-500 (Pandharipande P)110 (, Cotton BA, Shintani A, et al. Motoric subtypes of)]TJ
-0.008 Tc 0.007 Tw 1.6875 -1.25 Td
[(delirium in mechanically ventilated sur)20 (gical and trauma intensive care)]TJ
-0.02499 Tc 0.013 Tw T*
[(unit patients. Intensive Care Med 2007;33:1726)-25 (-)-25 (31.)]TJ
-0.02 Tc 0.02 Tw -1.6875 -1.375 Td
[(41.)-480 (Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
(Clin Psychiatry 2005;7:268)Tj
0 Tw 10.39912 0 Td
(-74.)Tj
-0.019 Tc 0.019 Tw -12.08662 -1.375 Td
[(42.)-481 (Product infor)-25 (mation. Abilify \(aripiprazole\). Princeton, NJ: Bristol-Mey-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
(ers Squibb, February 2012.)Tj
-0.013 Tc 0 Tw -1.6875 -1.375 Td
(43.)Tj
-0.01401 Tc 0.013 Tw 1.6961 0 Td
(Muzyk AJ, Rivelli SK, Gagliardi JP)Tj
-0.0135 Tc 13.91348 0 Td
(,)Tj
-0.01401 Tc 0.48641 0 Td
(Revollo JY)Tj
-0.0135 Tc 4.27607 0 Td
(,)Tj
-0.01401 Tc 0.48639 0 Td
[(Jiang W)90 (. A retrospec-)]TJ
0 Tc 0.022 Tw -19.17094 -1.25001 Td
[(tive study exploring the ef)20 (fects of intramuscular aripiprazole on QT)70 (c)]TJ
-0.024 Tc 0.02299 Tw T*
[(change in agitated medically ill patients \(letter\). J Clin Psychophar)-25 (macol)]TJ
-0.02499 Tc 0 Tw T*
[(201)35 (1;31:532-)-125 (4.)]TJ
0.02 Tw -1.6875 -1.375 Td
[(44.)-475 (Endo T)75 (, Katoh T)75 (, Kiuchi K, Katsuta Y)130 (, Shimizu S, T)70 (akano T)75 (. Famotidine)]TJ
0.013 Tw 1.6875 -1.25 Td
[(and acquired long QT syndrome. Am J Med 2000;108:438)-25 (-9.)]TJ
0.00999 Tw -1.6875 -1.375 Td
[(45.)-475 (Lee KW)90 (, Kayser SR, Hongo RH, T)70 (seng ZH, Scheinman. Famotidine and)]TJ
0.013 Tw 1.6875 -1.25 Td
(long QT syndrome. Am J Cardiol 2004;93:1325)Tj
0 Tw 18.2724 0 Td
(-7. )Tj
0.011 Tw -19.9599 -1.375 Td
[(46.)-475 (Nakamura Y)130 (, T)70 (akahara A, Sugiyama A. Famotidine neither af)20 (fects action)]TJ
-0.019 Tc 0.019 Tw 1.6875 -1.25 Td
[(potential parameters nor inhibits ether)20 (-a-go-go-related gene \(hERG\) K+)]TJ
-0.02499 Tc 0.013 Tw T*
[(current. J T)72.4 (oxicol Sci 2009;34:563)]TJ
0 Tw 13.06836 0 Td
(-7.)Tj
ET
0 0 0 0 k
50.5 14 378.5 14.524 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.02299 Tc 10 0 0 10 50.5 21.6856 Tm
[(e1)57 (1)]TJ
ET
BT
/T1_2 1 Tf
0 Tc 5 0 0 5 73.1366 23.1856 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 86.3177 21.6856 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 219.4427 23.1856 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 232.6237 21.6856 Tm
[(2013 February)55 (, V)110 (olume 47)]TJ
ET
0 0 0 0 k
463 17.694 80.5 10.806 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
0 Tw 10 0 0 10 488.4582 21.6616 Tm
(theannals.com)Tj
ET
0 0 0 0 k
50.5 740.1929 234 10 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.0251 Tc 8 0 0 8 50.5 744.7228 Tm
(S)Tj
-0.02499 Tc 0.013 Tw 0.76835 0 Td
(Nelson, JG Leung)Tj
ET
BT
0 g
/GS2 gs
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 284.35733 11 Tm
( at UNIV CALGARY LIBRARY on May 25, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
16 0 obj
<</BaseFont/GUCSMB+Times-Roman/Encoding 13 0 R/FirstChar 32/FontDescriptor 15 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 833 0 0 333 333 0 564 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 0 564 0 444 0 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 722 667 556 611 722 722 944 0 722 611 0 0 0 0 0 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 564 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 444 444 0 333]>>
endobj
20 0 obj
<</BaseFont/SBQZQS+Times-Bold/Encoding 17 0 R/FirstChar 44/FontDescriptor 19 0 R/LastChar 101/Subtype/Type1/Type/Font/Widths[250 332 0 0 499 499 499 499 499 499 499 499 499 499 0 0 0 0 0 0 0 721 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 443]>>
endobj
32 0 obj
<</BaseFont/AYNBDC+ZapfDingbatsITC/Encoding 29 0 R/FirstChar 110/FontDescriptor 31 0 R/LastChar 110/Subtype/Type1/Type/Font/Widths[761]>>
endobj
28 0 obj
<</BaseFont/NMVPJF+Times-Italic/Encoding 25 0 R/FirstChar 32/FontDescriptor 27 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 250 0 500 500 500 500 500 0 0 500 0 0 0 0 0 0 0 0 0 611 0 0 0 0 611 0 0 0 0 0 0 0 0 0 611 0 0 0 556 0 611 0 0 0 0 0 0 0 0 0 0 500 500 444 0 444 278 0 500 0 0 0 278 722 500 500 500 0 389 389 278 500 0 0 0 444]>>
endobj
56 0 obj
<</BaseFont/RSQKYE+Times-BoldItalic/Encoding 53 0 R/FirstChar 32/FontDescriptor 55 0 R/LastChar 122/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 722 0 0 722 0 0 500 0 611 0 722 0 611 0 0 556 611 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 500 444 333 500 0 278 0 0 278 778 556 500 500 0 389 389 278 556 0 667 0 0 389]>>
endobj
69 0 obj
<</BaseFont/Helvetica/Encoding/WinAnsiEncoding/Subtype/Type1/Type/Font>>
endobj
53 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma/hyphen 65/A 68/D 71/G 74/J 76/L 78/N 80/P 83/S/T 97/a 100/d/e/f/g 105/i 108/l/m/n/o/p 114/r/s/t/u 119/w 122/z]/Type/Encoding>>
endobj
55 0 obj
<</Ascent 700/CapHeight 669/Descent -204/Flags 262242/FontBBox[-200 -216 992 921]/FontFile3 54 0 R/FontName/RSQKYE+Times-BoldItalic/ItalicAngle -11/StemH 0/StemV 79/Type/FontDescriptor/XHeight 685>>
endobj
54 0 obj
<</Length 3414/Length1 3414/Subtype/Type1C>>stream
  RSQKYE+Times-BoldItalic   Cø øøøø€û\ûlútú-
 ‹‹
 ‹‹  	    D¯  2 }“002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku Bold ItalicTurku    4  / F M T P O  + ( - V H 5 S B E 1 J U " G N X  % Q [    |  íP™WÈíDÂ£Y«ıu zç4‘		Î
D
`
ÎO®-y­ù®‡wğ÷÷÷ø÷Åø@G¿}Ÿ·Í±³ËÜµYû•¦‡ø³÷\ny„uø]l¨‹Aû26!û?÷‰_‹û!FVVC!^áñˆmŒhûs©§—’’¯·hæ÷äÛ÷ŞiÈûíü$Ó‘vš¤øÿ¤pù™ğù~ù1ûerÈ…}cx„j€b<û²ûlødûVrÁ†–„`ûü.eû„‚S}r÷e¤Rr±’ª—¸í÷÷ğ÷–ü¹¦÷#ø±÷•Å•ûb~Ë÷«÷l¬÷#û#÷÷>çô÷(÷j÷«¾àº”u(AM8v÷<CLegocì^u§ÁœŒ”¢å”÷:Î÷½`¯Oû'û"û<û13ÊLâÙÂ³íÄü—v÷³÷µùP3ym‡1‚q¢³jw}\„q'ûÿ}W„j‹zb¤sµÜ¼ÖÇ²ušiUqqy‹‚…’•—’¬šÀû™“vŒ¨ø1«Šw¹ë´ê\÷ßøao{ƒ…†}|nv¡‹^:VZ?T™nÎ=³[›mrlrsjYjºá~qüuû:¥™““‘™|¡¤x‹·äÈÂÙõûÜ‹Ò§Ÿ¢«¸©c<˜\¦ˆû*}©ø5¨ˆ÷÷`÷÷¯øbû'ûû3û;5ÏKç÷%÷÷0÷9èLÉ.ƒn©ŠšvaBSû¬+iy¡·Ö¿÷­ö†-—v©vøbw÷wp÷…øaS~Y„.…p «Œoqj Š†‹ƒlPûh÷÷èâğ½¥˜–‚~i4û[‹:ğb£u¸Ä¼´å¾u˜eP}{zŠƒ„’•¤ã÷i‹Ö½p¢X6N/*J‰ü$Åà\ûI÷¹ÙæŞÃh³Ybnl`MÑ‹beZ[Flû*(¯ùW¤]÷é÷øNøÑ™À™—À‘¤û¼r¦ˆ¹Šh‚‡wƒnûüEeû%|kh‹x‘— ¢‹©­o¦fhpldQÌ`á÷ËÆ÷®Óy±÷±¤÷Ô¯ ù?ù:ùBnt€~„zl`©4û5kG>*6Rûûû5÷û÷GÒ÷  ¤½§™»÷HÒ‘Á‘¤û²r‰˜–Š‘­‡•‚rp_û?}{y{f_(NÑ÷÷/è÷º÷Så¸Pû¨†d‹«øø¤uø÷øÉ÷\ûI+Uû_v• ’™–÷ør™Á¡›ËŒ¤ûÏrÉ†—…p€†o…wûüV~Zy{Z„rø¼Æ÷W-—vø_w«wšøpĞø{øVû
aû&wUgGfFZXn‹}‹ƒ”‹›‹–¡•¬ğé÷ÉEI|B‰p»‡“‡u}†s€f_û+‚k…j‹xV£sÀÂ³¦ØÃ“–‘ª¶‰{\…opc¡w·ÄÅºÜ·v˜fUxx|‹‡‘˜Ğ™“¯š¾û*û_­÷Kv÷4«÷‹ªWâ‹÷÷÷ @÷	ö÷„Øo‚¥~šwt`_qEC^©»·È³›õ÷!øK¨œtcWiûEn|Ÿ±¾¬÷ĞúûCü>+uipSN×`÷ ÷&ëÇæÇg¬ûªVši•y™‹››œ˜š™ƒ‹ õ÷êÚíœŠ’‡ÎÃû¥ik“aû$9*V¦dÀv9]}}emw´|d‹¤øõ®i­½øëğùù1üºeû?¤„¹ìÉ´÷‘û'ü¯|UrzI‹r÷ß¤C€‘ª˜¨‘ ğ÷øî†ªh“û¦‰û™ v÷×÷ vø-÷wøcQ|‰‹û ~p¶Š–†w}V~]>û¡÷½÷2©ëÊö¥‹œ“e‹®®£©·´u¤h\`XûJ†û*’vÑ÷ÿµv÷p÷ø9¢Š™xnIHûŒ1rx¢ªÌÜ÷Ş†÷P¯û…yS‰·…s£bûû)ûRû3=µ[ÎÇ·­çÃŒ€b‰ƒ‹}ğd§p³¸½¶ŞÁvšfWxx|‹ƒ†‘•§‘¨§çû*ÓDÒ÷ıµv÷p÷¢ø9¢šwkbDû /rz£®ÍÛ÷€â÷Š÷«FyW†4…p §˜‚w„‡z…ueût£w”p‹û
û/ûSû1ğB¸UÇÌ¹¯æÀ‚cŠ‚{pd¡u±¼¼µß½u›mZwu{Š…Š†‘“¢º÷:”¬d‹¤÷¹®÷±ªs£øe÷&è÷àøå±•“’¬¾ªiRWyMrhmud|S€„‹x‚k‡²œŠ¤÷7÷ Ù÷
òD¿û"û²øsÏ‚‘ˆo~‡u…tûüV}YUr÷º¤Q~“©—¢‘¡ü—vøÃ÷÷÷÷Vù@fmmff©m°°©©°°m©f¨ûr/z…Š#q¹Š—…r†‰„‡{Sûl€b‡v‹|e¦q´ÇÃ¸å¿u™jWqox‹ƒ„’“”Š‹”®‹È÷zª÷ü—vø4¶€÷·÷‹øçhZ>^f2dh¾Lûp‚mxF‹n`¥r¸Å»³ëÆu™gStsy‹ƒ„’“š“¯œÈÈ÷oŞ¶Cœ‹¤÷L²øHwø÷ ø/ù@süüàm\x{hƒr÷Y¤Zz“¤–‘”›Çò÷j‹š7‹_d|€K…r÷Ã¤K„“~Õû\ø±û‰ûMûÑû`÷ûªøÙµ÷÷‚v÷÷	û÷ª÷€øVÒ¤ì©¾­‹—‘‡ƒ€{‹w²o u¦©  «»d«Qû @8û:_BƒaôÔ|N„m‡wMû­,v~-S€ƒ‘”›“‹¤´§wmoutn\³kÅ÷=½÷fø&Üä”µ÷—v©vøÔŠwøÚ÷h÷}øaO~~‰ûq·Š•†w„Œ„kû‹ƒkMûq÷÷÷æ÷­––’‚|‚‰~†|‹Gûoiû÷°÷µ÷á÷¹‹™•~b3ûO‹8è_¢v¹Ç´­ìÃu—eQ|z|‹‚„’“°ã÷L‹çºm¨YXL`û?œ¸¡¨ø´q¤b-DûH]ˆœ“vøow w÷Âï÷ÖØ÷é~ÖÛ÷X÷e÷±r¦hmqolc´w‹ineQ:/øl÷áoû-û¥‰Øˆ÷‚×vÑW‚X‚Wq°Š‘ˆ“v£M“ûF‰D‰6¦Äá´É­Ğ¯ÌŒ¢û®ûÑ v÷:÷÷ ÷:÷‰¢÷û‰Ó‹­øñ©r¤ø¬÷'ğçù1rÏƒ‘„o€‰…{Pûü?}X{|Y„r÷²÷•÷N÷9÷x÷DûïûTğIG§’›•®÷ÀNûûfûWCBWBf5ay–£ŒŒ˜‹‹—·û*û`¥÷:®øÓ÷Ô÷÷køc*{£û|p¹Š“‡w„nƒjûü>~X}€_Šq÷Œ¥XŒ}’¥§¥Ù•º{«›†¡÷÷"÷J÷<ÙbºIZ\p;R‰ïª£™xlADûˆ*uz› ¬´÷™´Û§º¸²û™<÷"÷¶ì÷‡ñøøVûË`û/§ˆ›¸››©‹÷$û¶ûö¤uš•œŸ‹ÁÇ7‹æÆº´¾§t¡lqutqmŸ†‹}‚‚…~zƒ’£~aÙzQ¥÷­÷åxøV˜÷b›š‹÷œ–üv¤
ÚŒ
_÷ù
endstream
endobj
25 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 46/period 48/zero/one/two/three/four 55/seven 65/A 70/F 80/P 84/T 86/V 97/a/b/c 101/e/f 104/h 108/l/m/n/o/p 114/r/s/t/u 121/y]/Type/Encoding>>
endobj
27 0 obj
<</Ascent 684/CapHeight 654/Descent -205/Flags 98/FontBBox[-169 -217 1009 884]/FontFile3 26 0 R/FontName/NMVPJF+Times-Italic/ItalicAngle -11/StemH 0/StemV 23/Type/FontDescriptor/XHeight 677>>
endobj
26 0 obj
<</Length 3398/Length1 3398/Subtype/Type1C>>stream
  NMVPJF+Times-Italic   Cø øøøø€û=ûmú…ú
 ‹‹
 ‹‹      ü  =¬  % }‰002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku    5 I F  " O B M T P G 1 S N D U Q Z     ' C V  7       Y ìLO³E¿|Á>³Ş+Ÿ ­Z®		˜	ı

»V†¦- vøÿ®ÆøÑùù"ü§aû.‡¡ºœ¤¥Ÿ¤¬¦‘÷û#ü¥}YszF„{÷¶›9‘‚«•‘¥’¥÷ ø‡ÁÖ¨rKŠ‚‰xœŠû*—v©vøOvø]ğøpô—_Qvwz‹ƒ„’•–‘™“Ä÷e•®‘©‹˜²p§fKFMû#-‰÷
øK…L}w†Bƒz¤ŒœŒ¤‰‹tuj|Pûü‹Ö±÷)›µ²ÆÁÜÍÆ®‹›‹—€‹}‹†Œ‹ƒnWûS}W‚ağpœ{§¾·®Ú»ûb¸ø¢ªá÷yÌø/ø
¸o¢Tûû2û9û&3¾VàÎÕ²ÏÉ—CQk{`‹Se°Á™Ÿ’¥¨÷, ò×‹âJ’7+Gûv·°æÏÔÀ Œš{tü$d v÷v¯ø+vXøûøÈ›Sƒ•Ó,øÌqûµü‰Aû}{bƒ{÷O›\~’¢˜“¥—¢Å÷÷pŸûŒŒ‚‹gx~PŠ{¾÷šûV÷(÷˜û*—v©vøNv™ø`ğønó|˜UFy‹‚…’”’ •±·÷4—·”´‹š°q¤e,4û&H^‰Ë÷e‡ût‘Œ[‚{¾‰˜†x~‚n…v‹ƒl@û§Ö´÷$¢Ã¼ÑÊã±¬¯‹˜‹•‹z‹€…lf`û7{PŠƒ|ğl›{«¹©¤ãËû*€¼[»ø¡œŞğøpï–~~YSy‹„†“•¦–µØ÷Æ…L„€[ŠŒ€®od‹ûû1ûJû-=®bÎÑ²©÷ãˆ{L†q‹wğo˜¨±¬¥ßÍû÷”3,ûz!dr§·åé÷q÷®¢qdü•v´÷‚÷«ù;†Q{ˆ9{¤·Šr„–v>"üv;ˆ}‹zi›yªÁ§¢ñÑ”UCwxu‹†‘•’š“©û™“v¢vøA£Œv÷ Ô¹Ø|øøO}}‚„‡~|nqœ‹cC[aJ-÷?‹@[nkaRl³ìz|üwû4š›’‘–|­ªx‹±ßÉÂÖêûÙ‹Ô¬¢Ÿ­½«g=•|›û*•vøYv¦ß÷¦Şøh÷¹èUÃ2û(û*û0û-/ÂWë÷ ÷*÷<÷8«)Bûmû[k°Âîİ÷p÷¶§fPüûMvøï«÷x¡¯êø:øú±g¦Xaexdjibu\j#0ƒkå3ü9tûlX_‹„‘•””‹™ zšsw}zsi¬q·åĞì÷MµÔ÷Õ÷ ‘« ÷0¦±ÓÂ™•†„Š†€‹|sš{¡¢¡d v÷Å°÷®©ø‰òøğøŠîBÀûûŒz«†±`}‡v`û
ü={R„…P€{÷‰›S’“§š—”­À÷U¶…¤‰±‹÷,óÛ÷	$‘ûOWûxt{Ñ÷‹‘ —“¨‹æ´g;û™ v÷èñŒv¸øğø0øªxŸnX@7(^‚wŠ¼÷[ğˆWW‚W‚{“Œ“ ˜y~…ih:û¹×¶÷ š´®Ğ°ÕµÀ ‹ğ f‹¶¨œ«Ó—v©vø¿\º—ùFxùRô}—ZOxyzŠƒ†•”Œ’£Ä÷g”­‘©‹˜¯s§k24ûHa‰¦ã•±‹œ¯t£iO?Dû8ˆÄ÷[ˆ$vŒŒP€{ÀŠ–‡zƒ‘{M8ûÊÖªğŸßÉãxÑ¼Â»¨˜“‚|ƒŒ|T‹‰;ûº×²÷, Â»ÏºÏÁ»¦‹—‹”‚‹}‹†Œ€^ZûZ}Q‡z~øoš{¦¹º°ØÀûb€¯ø5w©àø<÷ü½a«Hû%û û'û.)¿UëÔÉ®ÔÀ{”cZSk[‹Sh¸Ò÷$ì÷ñ£šƒ{|‚‹ru›|£¦¥ü–vø+¬¯÷˜÷¼øB;§òŒ‹‹ˆ……ŠŠ€‚\Sbib{m€‡ˆ‹‹‚‹”‹‚ÖBû§t5Œ‹‚uŠ y¦¤£–Ÿ¢›˜œ³Ä~‘rlpj{}‹…‘–Œ›ß÷Òßû*ûMv÷Wø¶øåøi÷Éßa¼BL[l=T‰§î‡’û0uz©­ˆ‹p„†s‚jûüN~Y……[†|÷bš\y”¡©¨ğ“®}¦˜ˆ¨÷!÷0÷=÷+1“û(û û5'ltš¡¹»÷(¹Ì¤Ä¼¿³¡mWûbûLvùv÷àéc³Ğø>ø²u£hàv{|wĞZÁ—‹dP,û/p]w÷…¬N÷qy‹vE}VzŸ“Œ”Á¤Yûl¼šG•V~{„|tmxqplww€…‚‹w‹}¨p‹t‹z{‹u‹pŸyª‹°‹¼²Ğà÷	÷#÷÷ƒ‹Úû*‹Öø¥ÔøàøWøíFÔ-*?Q%gŸ„²Íµ§É‹ÒÀWDP`C%ûûeûtz÷÷½÷z’rXv~U‹ûR÷U÷U÷
÷
©º‹Ïû*„§ù§«Ú÷ÈÙø…øH÷*Oæ(û.û,û|û~ûÎ0ê÷1÷&÷j÷y=âû*Tû]J5_jjvhUj½Ü÷½÷UÁîÆ¬·­·¿ª\<û* v¼÷üø-ù0‘‰‡„2v{+{ ¯‹‹£Œ˜€xƒ‹……wûü‚€e‚‡0}÷«™tŒK‡°’‰ƒ Ö÷#øšš”‹û*…±øïµ÷ÙÛpâĞøeø½ÑOÁ<FKcLlš†´¼¨œ·‹¾¯fU8,Iû$zŒ{¡àôÅNû3QCDzr–Ÿm¥e„wpz|rf´vÓ÷1÷÷÷#Ør´E­Ğ÷»¬«Òd v÷Û®÷—¬“ùùù"ü†{Ï…•†n}†p…tûüO{Rƒ„R€{÷›Qy–¨–Œ“©É÷sÅŠÁŠ¹‹Yx‰|…sœ…×÷x‘Z,“ûBˆÌ÷}‘¢•Í‹÷,ª~M}‹‚‰xŸ‰û*¡ø¼øàøn÷ÔÔ[¼D2V:J^Šğø†U‚‹#|{ ‰¸‘nyf‡{ûüŠˆrÕnÉ÷)÷:÷B÷06~#ûûSûh|—¦ìë÷‰÷µ§iWû*€ÀmvøNvªv÷à÷¸øo÷ }”[Nyy|‹„…‘•—Œ˜¼‹ Ù÷¼AaûrT`HP/XUn‹q‹¥“æø ¸ˆQ}zˆ@€} ‰²’lƒ‹Š‚gYûW\†p‹zgx¯Ğ¾¾÷O÷hûƒhwølœy©Ï¯Ğ»®ü$‡÷÷¬³s§invxpz’{š}ƒrurVg•xà¼¶Á‹Ædvù4v×øøùDù›ûN{¿„–…uy|hfKû^ûó‡IøJŠ‘‹‘‹«š”É’›û…{À„‘ƒ™9çüÃøøı›¦™•¥û* v÷EÍKËŒøq°ørù:cü5üCwG÷™ZûGÚğº÷EîšÍ,™÷×,û×ûi÷Å÷Õû*˜vøïÔÖøaø¬ù&…•ü
:û˜‚¼Å¥™Æ‹÷rˆüüìÒü$€÷¦÷÷·ªr¤mlrrlm¤rª©¤¤©xøA™÷g¢’‹÷¡üs¡
¢
_÷ù
endstream
endobj
29 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[110/a73]/Type/Encoding>>
endobj
31 0 obj
<</Ascent 1667/CapHeight 1667/Descent -293/Flags 4/FontBBox[0 -143 976 814]/FontFile3 30 0 R/FontName/AYNBDC+ZapfDingbatsITC/ItalicAngle 0/StemH 0/StemV 0/Type/FontDescriptor/XHeight 0>>
endobj
30 0 obj
<</Length 178/Length1 178/Subtype/Type1C>>stream
  AYNBDC+ZapfDingbatsITC   6‹û¹Ïƒ
 ˆ?‹‹
 ˆ?‹‹   h   e   k‘   ¬ a73    ‡ %<ø
ú0û¹ÉıÌù7ùÌıYVøçúüçäú!ÑúsúsøÍù
endstream
endobj
17 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[44/comma/hyphen 48/zero/one/two/three/four/five/six/seven/eight/nine 65/A 101/e]/Type/Encoding>>
endobj
19 0 obj
<</Ascent 912/CapHeight 676/Descent -203/Flags 262178/FontBBox[-168 -218 998 934]/FontFile3 18 0 R/FontName/SBQZQS+Times-Bold/ItalicAngle 0/StemH 0/StemV 25/Type/FontDescriptor/XHeight 921>>
endobj
18 0 obj
<</Length 1549/Length1 1549/Subtype/Type1C>>stream
  SBQZQS+Times-Bold   @ø øøøøû<ûnúzú:
 ‹‹
 ‹‹   ù   õ  °  è }‡Œ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku BoldTurku           "     F     < “ ­bzà mİE°û+‹¤ù+w÷O÷&øN¤1x›×øÍzûûq Ä™™¤—u\ü:wz(Šrû+‹÷øM÷÷½÷øq÷hrEo|‚(û*÷3÷.ŞÛ«Ç‹Ö÷@×û*DIûY¦Ä¥¶«¿Ğ¼V@YwSaN^K]Uûûsø3ûÒ v÷@÷·÷†÷²÷@÷û†ûû+ v÷#÷øEw÷÷&û$÷$èøm÷#÷MøE;dYk_xrûû4‘#û2ûğ÷Šû#÷&÷#èû$÷ûcğ÷a÷»èû+ƒÇO÷(÷S÷Ü÷ø	Ø¸øiù8ûÕ+ûí÷
ºƒ»uÎm´VTU^\XøDZã‹BgqrhVÈhå÷4÷	ğ÷ÜfÍH³V«e“û”¡Ü÷©û+ vø¯÷œø^øoù8ü3`ûr¤Ëœ£ Ã÷bûZü¯êû+~ªù§§÷û÷÷9÷û÷
Øøj÷MãbÇûÒÔâ£¼½ÌãAÃû
û 6HûA³UïPè"l]X5&áH÷÷çÚ÷Ôû÷ôa‚gjeR¨CÄÒ¶±±·Â­]?è…ü+Gi_XOeÁàÅ•ª³Æ÷C£kDÒ‹¤÷@²øZw”ù9ùB£]—W÷ûsø¢nûpü¸e.‚Yr÷_¤Ot—¤š˜±«Ù÷s§QRt~ƒ|ˆ€ˆ‹Y†r÷€ûVè÷‡û+~¥÷„¹÷ı¦¥øRølø&÷>.÷ûû1*ûûÕ9ö°£™¨]û0DDû(kq÷¤÷C÷8÷vû1¦hŠoƒS†s…xMtÅ÷5÷—¨»¡x•›o–62ü$šv£v²÷Là÷sµÍ`ºO[jj[[©k·à’’‹“—“‚}fkd>S–tÉ°¢¦©¬± ¾»û+~§ù§£øVøn÷ß÷b,÷*ûû,û+ûaûZëû&÷÷ë÷&÷Zû2û û'wN\\wÈ÷'÷y÷&ŸÈººŸNû&û+}÷(û(½øÏÛ÷­÷&@÷¨øf÷‹ÜbÇ:¯°Ë±©ÇŞM¿(&@Y$U ®Ç°¤À‹Ç²bMIig,mxè÷ `ÇP+EdZT¨Dqí‹7iprlSÇgé÷9÷÷÷&ûc}Ó÷O°÷4©¤÷$û$÷÷÷ôø<÷t™aXo{_‹BcÊ÷†÷÷*„JØû	û6'û û&İ'÷ŞÁ­æÇìû÷?û÷ »½¥Ÿ{l’‘u‹ƒ8û+~¦÷ş¹÷„¥§øRøn÷p÷AŞû kx‡}e³÷*ÑĞ÷/²¥û¨jû8û/ûwûBæû÷"÷æî÷û-KûnZuy–¡€|¦‚Úåµ¨‘º’Œ “Ì¢Qû6xøa—÷_›÷p”÷Ÿ“üu¤
¤Œ
_÷ù
endstream
endobj
13 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 37/percent 40/parenleft/parenright 43/plus/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 61/equal 63/question 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W 89/Y/Z 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 147/igrave 177/plusminus 210/quotedblleft/quotedblright 213/quoteright]/Type/Encoding>>
endobj
15 0 obj
<</Ascent 684/CapHeight 662/Descent -215/Flags 34/FontBBox[-168 -218 1000 899]/FontFile3 14 0 R/FontName/GUCSMB+Times-Roman/ItalicAngle 0/StemH 0/StemV 84/Type/FontDescriptor/XHeight 677>>
endobj
14 0 obj
<</Length 8321/Length1 8321/Subtype/Type1C>>stream
  GUCSMB+Times-Roman   @ø øøøøû<ûnú|ú
 ‹‹
 ‹‹   û   ÷  š¬   ` }ˆ002.000Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku RomanTurku  N  B M P Q F S J E   G T U  H O Z D I C N W V 	 * $ 6 
  4 ( " ) X [ R 0 Y & 5 L 1  %  2       '   .  + / 3 - K  œ    8 #  : , ; 7 i w   Ö  P    È›ùfÁ9uxÕd°Ç‘~Ë9›M®		V		ö
\

½7®zQ¾gìbĞ4OĞ?¢Ï4…ó,²–Ş>´úeÔÑôPïÇ5¹øT½#÷"ûb–vŒÄø¤°ã÷6İxøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½¸T‘x·ª§›­§û0ßsˆ€ƒx{yb{sfo­¹Èºµ÷±ü vìß÷”›MŒ~—Ãøç‡Hwv…Ey{Œ™’‹—°“€YüpV{}N‡{û*‚¦ø4§¨ä÷šäøi÷~÷0éûû0+ûûç'÷÷êó÷2hû^FA8O÷÷*ç¼ÌĞßÇ*ûû*ûVv÷a«øÇŒwÕß÷vàìøi÷ˆ÷Fä*R_sVa‰ÔÜ…TvŠŠ4m{Œ—‹—«‘[ügU„„M„{÷…›AŒ}—É÷0m«©²÷æ÷÷$6fûYAArm—s}—‚—•÷Šì¯“»ªºÕ¼>ûûbĞ÷o«÷¯¤ĞFÒ÷cñôø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½ìû÷-ûcÙš®¯ÇÆ¥m7—ûÑ vø`w wÖßĞ÷âø+¬wŸhblsH]‰ä°†Jqw„Mu{š“Œ•¤•{_ûY‚ƒN{÷ƒ›KvÄ÷sœ˜¤™˜™“”’“‡ƒ”x “‡›¡›¥ü vø^w÷$ğ×ğ8ßğ÷Eù§t¢opttop¡t§§¢¢¦Öı›èK–Ó÷÷†WwZyVy|©Œ‹“¦”{_û{CGˆ{û*¿ø§¦á÷wßøµ›ƒ‚Š‹‡f‚—¸øË†Ux|‡=v{Œ˜‘‹¯“‚aû0¬cr•bû.ûûû×2÷Àµ ¶ªNˆÙ§oë­û+Èm^l_9SŞ÷÷¾×ÔÂ»\Uü$›v£vÃ÷  ÷X–¿h²\jrskl¢w¯`™‹”•‡Š‰iogVg•xÎ­¸ÈÄü$ûÑ vø7«÷_¨òß7Şğøù«\§UûQAû2Š:kÜûÏB€B‡{÷˜›:–Ö÷Ï÷«èû÷Æ§² ”…oŸk¡”„œ¢¢û™‚¡vøZw’¢¾È÷:Ñœ÷ğ÷»t«M° Ënœ|¤‹©¯­¨¶Å®d6œ›¬‡÷ƒ†‡‰…†„Œ…œ™cs:QXDOªeáZÅj­xq‹n_koYEi¯òs{\û/˜”’”“•Šˆ–œ´¤‡¥ÙÊÄÓü¿ø«Ğß÷ªÍ~–vrzt‹g|¦Ê÷³ğ«&÷–‰…U<midp„†‰ˆ‹…‹‡Œ‰‹¿ûÂ5©bÉ¸²¤¾¬ûÑ v÷UË²÷Š÷±÷UËûŠKû*ûnÄ÷&Ö@Ôæ¤÷k²§§ĞnŞ÷EÙ¥¨İÀøiø²?u~“w]tm*AE-L¤hĞgCKyvtuš|²{¾ÀFZnfgTØ`ï÷÷ÙæÊ]´@ûTs•‹”˜™˜—˜™“”œ†¨çÏÍä¨‡|°PûSnf_İÀMaÌíÈ¦®»Ä¸B.óûŞR?bûŞÀ3M©µ£•œ²¹¬„›‰¤ˆ»‰À‰ğˆ¡€‹iû* vø)ÂŒwÚÜ:ß÷EßÔøx›]}›¼÷yè^ÄB[p|IDÛ¬„Yxˆ@ty™‘Œ“¦“{[û‹S}z\‰{÷gšY{˜­÷­Ì»Ã›”¬»£kJûeN}xZˆ{û*ûmğøËw™ø`ønøI™û}¯ˆ—„z„”qB<ûqû÷‚‹’‹–œ’’½‘™ûa}¨†—„”w÷ûŠ¦P®J|tpG{rt|z||wuloxzpkªr´Òµ¼÷*Ä÷/ø-–©™˜¡ûbÓø¨¤×ø0÷(}“`HapQ‹1Kİ÷ğÄÔØ²–‚c—‘w•kš|£‹¦¥ÁEº<û+!û!ûÚ/÷ßÆº÷Àû* vø+ÁÓß÷Nßøz›X‚—Ğ÷[öaÀ9R_rQ`‰÷Â…\{˜ kzŒ“‘‹°“‚aükF‚U†{÷k›T~œÎ÷…¹µ«±º¦eFûZG€}R‡{û*«øËÏß÷wäøh÷‡÷?è$SWlXp‰÷Á†a{U{[~{Œ•’‹®”cüœmãiÚ÷ò÷÷!2bû	]L5[\££÷¶µ¬Ä×¿;û÷ vø-¿Œwáß÷Lß÷KŞÜù™›RŒ•»÷c÷dÆ=SXpSUÅxk¤Sbv‚XF†‡ƒ†ƒÖ¼ƒZyŒ‹1py›Œ–¤•x^û’V}}S‰{÷r›Yy™°÷¯••—•Ü£¨«—ª»¡iCûmU~Sˆ{÷s›SŒ|œÈ÷¸«ªœºÁn9ûgS„ƒP„{û*’vøewø\øoøG›û{«Šš€v|‚oy]=û[%÷”†˜‡œ‹’œ˜”¬›ûW{ŸŠ•†—¤s÷û¿£N‚˜e”‹’‹’·÷÷Ô¦Î’”©û*Äø(wÑß÷Fß=Ùèør¯™YŠ–º÷ìû2{ğË‡•‚Yûrˆ€ƒuy^wlcj®µ÷Ûû%{»ˆ˜~[û;ºY×¯±›¦¦è·¶9ˆÙ§”¾™ûÑû1vùêw»à÷Äû6ûáZ÷÷l÷[¶ñ÷î‚›û@û@û‹ûLûµ#ë%²a§t²tûÑ‹ù÷ñ÷ÌŸ8~—ÖøOÖ˜—ŞŸûºwŞˆ˜@üO@~8ˆwœ}·øOv÷M²§÷ù÷yœ=AOp5‹û+,÷÷K÷Så÷	÷(öÒNû°¡‚÷tvƒu|wŒŒ{x’b™Y“a‹ûZ‹û!û#‹û]‹ûf÷û÷_‹÷‹÷ ¿¾×Ó}·øúòò÷ü¶ùSùŸû{wÖ‰r(û¢=`slakTtJO\®nn®‚°Û÷ÔÔ––ÚŸû®yÚƒ•BûËû@İ6÷:÷HÙİ÷P÷™ğ› ÙûÑû1vùêw÷\à÷±÷Š÷aó+ñdµo¢d¢{÷5¼ûûlû[`%û(”{÷@÷Ö÷‹÷Lü$€÷Ñ÷÷I·ªr¤mlrrlm¤rª©¤¤©-~¯øø´Ñá÷~ïø~÷<Û\ÄûÕQ­"¼ÜÀµ²ÆåĞLû ¦¤u÷hvs…‚z„|}ŸOw‘q"?D)9­a÷C÷>¬hNGZ\C0MÀ÷Wu©ûh  –—¯«jç÷
ãØóÓ}³÷É÷®³«÷øëùW÷ãû’xÙ‡•@û4iOq?û3'÷
÷O÷Kì÷÷%ôĞUûµ£ƒ÷fuu„{€s…€€¡Ej‘\û[û"û&ûbû|÷A!÷K÷÷Â÷\Å™šÃÓ‹÷[´ø4wšùGùVŸ^}˜lÓûøÌwûdüOû!}xY‡w÷ZŸ\Šu™ª••‘›¹÷
÷š´*•t”l‹pzƒWw†÷—û{÷÷§Ó‹÷¼·÷±õñ÷ÃñùPŸA~˜ÓøQÓ˜˜ÕŸû¨wÕ‡˜~CûWûÃ÷WÓ˜˜ÕŸû¨wÕ‡˜~CüQC~~A‡w÷¨ŸA~˜Ó÷b÷ÃûbC~~A‡wÓ’v¡vødw ù4pùIøG›û{ªˆ˜y~‡u~l0ûr<÷ktÉ„‹˜£™“¶›û^{µŠ™v­%/û\kâH÷C‹†›Š“’Ÿ˜”¬›ûG{¢Š”€ŸX÷ûék˜‘’‘‘”©™÷÷ƒåû°^œ‹Œ’“ŒŒ»÷÷îœµ’ûb‹©ø©¦øø6÷yv*|~/‹û÷¢ø*šûïˆûœÕ•™šÈ÷ûü*|øû*ûVv÷aÉø§£à÷|ßø|ûk›]zš´øê†NgUª|_‹û,ûû&ûÍ4ìÀÀ¤»¹ŠûNT|~A„{ä÷ëk„~t~sr…s>W×÷÷	ÁÙÜÍªkFÓ}¯øş¯­÷ø?÷ùC÷Ş÷_û÷#ûSûTûû#û_û]÷û#÷T÷S÷÷#÷]ûŒûT:û	ûû:÷	÷T÷Rİ÷÷÷ŞûûRû* vøWwœøbøs›hy˜n·û÷Xß÷¦§›­Œšû3}¬‡’‡}~uU?~Ÿ…s³xª„š‹“‹›•‘«™ûb}µŠ‡°Sêû%ûû9pd}lŠ{÷%›n€—“—™¡Û÷Üû›s‹Š‹€{€„r‡{d‹±e÷Èµb´÷“²xîğ÷œ¢¬¢«€øè÷>oû ^]sû7#²÷Œ÷.‰ßŠ–‚š6¢÷|t6|8û.÷q¨§÷÷~0¤‡÷#ü¥W€wÕ‡˜~CüQC~~A‡wø¯d‹øí¶Ÿ¡÷gñ÷|vøãø„÷>üÄ„û>¤÷¡ ›÷Áü’@~8ˆw÷ºŸ8~—Öø’Á÷ {û¡û* vİßø›`i¡d¼û.÷V¨¦ïè½®Ì‰™û_}“Š‹¢Š”‡Œ~Œƒƒ{|ûû‰ø3†Oxz†>w{Œ˜•‹’¯”ZüuU‰‰B€{÷~›M~”´÷I÷ûLr‡‹…ƒ‚…y{-‹÷¡³÷½±xîò$ñ÷{÷Úø±øw÷$Ñû3ûšwÕƒ“‚DüFCŠp9‰w÷¬Ÿ<Œ|šÕ÷HŠ¤¢ŠÚÅ–¡²È­®ÇÏû‰!S\ûæz‹t÷™§’‘­÷ÍY-û*~°øâàÙ÷ùÑøJù?‚‘yuƒ‡w‹ûeûû€Š‰Šˆ‹‰‡‰‘Š÷ƒ÷5Yû.&O?;u„«^¡l}pr}~tb·uİ÷5÷ ò÷.÷@ûÄû)¦µà÷XœŒ’Ó‹x°øá°xòñø÷œù?÷â÷bû)÷ûû wÕ‡˜~CüQC~~A‡w÷¯÷‚÷&÷÷clû…ûU#)ûa\~”«ø­”‘Á÷Q÷	ûûLü’vùFw‚÷º÷±ù8IûxıFÎÓûF÷Gwù¯­÷ø?÷ùPûEûŒ=¶5÷ ÷2¥ò÷‹÷E‹÷_û÷#ûS‹ûT‹ûû#‹û_‹ûÁûâS®u©}¥…¹T=Í÷_÷,’Œ‹Œ²ûøûT:û	ûû:÷	÷T÷Rİ÷÷÷ŞûûRûÑÚ÷ ÷oøŞ¿h²\jrskk¢w¯”–‹“”Œ‘†Š‰hohVg•wÎ­¸ÈÅû* v÷;ËøQw÷·Ú>Øèøk÷;Ë&øQ_ûÎüQK÷­û;Ø÷;ğ<Ëû„÷‚÷éû*~¥ù¥£ë÷˜ëøp÷ß÷c÷EÆ¤nd˜[[d~rnFPbûûû³ûÑOr¨²~»»²˜¤¨ÑÇ³÷÷+ûh`!44`õ÷h÷i¶õââ¶!ûiû*™vøèÔŸø@øTùšü|_`%œƒ²Ì¢›Á‹÷mûZüèÌû*}§øº÷‚š­ç÷‘äøh÷m÷Bßû[w„eLª÷1îê÷;«‡šûv‡ûMû;ûûDäû÷÷áê÷2jû cME4Sé÷'²­”™¡˜·´å¾Cûû*‹×ø¤Ô÷åáøn÷~md†pP‹û„÷=÷Dâæ³Ú‹Úí:Ù&ûHKûlŸ†¯ê²¯Ó‹İÄP6?\*95ûFûP~ø-‹÷Èµb´÷“²xîğ÷”¢´¢Ïøµøœˆ÷#ü¦wÕ‡˜~CüQC~~A‡w÷«Ÿ@{šÒ÷p÷&‰ßŠ–š7¢÷|t6|8û&÷q·¨§÷÷~0û* v÷iáøš=Œy–ºøí‚ûG0~¥•œ’œ”‹¢•}jüm\y€=Š|û*~§ù§ÃÖFÕ÷oĞT×ÔøQ÷0Øi»ûæØîÁ®µÎŞCÅ#!;H0J¢iñ4äû<ulG&ØI÷	÷
ØÍòØ1øPuiCVT¯E¿ÔÄ¸³ÊÏ¶_Gä™ü-G__IAUÇİÎ±É¾ªt”„‹èE£rN÷ƒ‹ùö·øœğùïŸFyĞøQÓ™™ÔŸû[ûoüû{øûZwİ†˜~Dü+&|x;„w÷}Ÿ@x¥íø$÷ü·™÷øÎüV9€~<†wû*}¯øçÆ÷ÑÚgÒĞøC÷lêk¹+·àÏ¹¤°ÅÚKÂ/,MXûdš‡³Ö¸«Ê‹Ì¸^L^r_cnpwvWyÁ¦†zªĞ»p¨XO8QICqv“ h£c‚ys}~ug·vÖ÷1÷ë÷û™’vù&÷CñøùŸû´wÚ‰™}Cüd\€wq|†‘£„²|›qqutp_²nÆ÷ ÈÓ÷øÓ™™ÚÓ•v–ù÷ ¸ø1·xùTùŸû~wå„‘k4ûã‰üøuû?w¶Œ–„µ[üM%~y8ƒw÷Ÿ>z£ğø¸øJü¹œø¤ïšŸÚ‘œ‹÷Á¤÷®¯xññ÷}÷Üù'Ÿdv—p¬ûb÷‘÷¢ÄÀè÷/Êû7û§wÔ†—~DüD4…„=ƒw÷¨Ÿ=’—Ò÷XÃ÷‚ûÉNø"Kcû=Š÷Šì¨—’½÷Å]1d‹²dùîğ°øè÷Bsû
SizûI0°ønÓ˜˜ÕŸû§wÕ‡˜~CüQpC~~A‡wø­üûXvù7w÷$ğçğ8ßğ÷Uù§t¢pottop¢t§¦¢¢¦èŒıø^†XwXyWy|©Œ‹“¦”{_ü!€jg}‚—€³i†wwwywk²tÂ÷ÆÖ÷"û*‰w÷—¶ø§©ç÷€ï+ëôø^ø!÷5/÷
ûû4'û û
Ô:öÀ»±¹øŒˆmû%ûû>qw÷…›÷3÷<‹÷ô+bv‡‚uod}j>\Õ÷÷±ÊÏä¸4û;5‹Í÷mÌ÷Ìø©÷¯Ìûo÷2Jû2ûoJ÷oû5Ì÷5÷oû¯Íü‹I÷K“v˜ª÷—®š«÷g¤ÏwÈ×÷r¤ÌÖ÷q¥Àù—÷šÑf³Hûû ûû;»WÕóë÷÷ûø2eYYbyDd{’ oŸr{‘oû û	ûB¾QÍõï÷÷™‰–‡ƒ£—‰£·§’ °‰¿ÀûğıºÀø…÷£û:û<du¥·ÏË÷?â²ªf^ü÷¼û:û<cu£¸È°æ¹½£¡¡˜œ‘Š„’•š„¨ƒ‘w‹}5 v÷Í÷Í©ø‹ø©÷ÕÍü‹Iø‹û]Íü‹Iü›v£v÷ó÷Û÷ û÷h÷Tø)©r¤lmrrml¤r©ª¤¤ª°§ü¿h²\jrskl¢w¯p•”‹”•‡Š‰iogVg•xÎ­¸ÈÄ÷º–vù"ú1ú6ùŸûZwÂ†™‚l|„k‚sûûèû÷épĞ‹Š‹—¤¡•ÂŸûŸwÊ‡‡­:­9 û¯û%øƒ ˆ•‹˜¡—‘ÀŸûˆwÉ‚‡ÒûSÌûC†èû¡š÷.ø;‘y‘|‚‘|¡Uª;±*œ[ª4™Ù÷ƒ–ªÌ÷H¦Ôš³–©šµ›—»‘œ‹°f÷È³c²÷—±x÷ñ÷†ğ;÷¦€øå÷DÅo½\§ršy’Z™g è¡²¶Ú÷.Çû<û¬wŞˆ˜AüQA~8ˆw÷â¦€÷%ìÒô§ û÷Ì<Yb)Š› -Š÷y§Ã÷È]0¦€ ûÈ*O]ûO|“¬÷÷VŒĞdûü€÷÷÷Ü÷÷Tø)©r¤mlrrml¤rª©¤¤ªûıªr¤mlrrlm¤rª©¤¤©Ó‹ù÷ÏñùRùŸûow¾Œ‚t‡€{û!ûxû)÷t€›…š‹˜¡™‘ÄŸû¬w¯‰™„§iŸt²W¥e÷ûTûM>~€2‰w÷ÆŸ2~–Ø÷U÷'÷wÁß¨¢Â‘Ó‹ù÷ñàùeŸXz–ë2û|÷÷Q÷QÇÇ£—ÎŸû˜wÇ‡’ˆtrxs4:tuº¶û@û0÷WàŞ–—Ù‘û¬xÙ…–8ü;8€=…x÷¬=‘€—Ş÷D¥¡õ!Ø>ÀF‹tày‚ˆO‰wd‹±øß±”øŞøç÷Dtûhjq%û–øCøöšü¡xû>¤òŸ°¨÷÷qüHüö|øÆÓ•vù#›ù;àùKùŸû`àxÆ†™‚m}„qmû&üû,÷æmÍ©‹™¤–Êûàw½ˆœ{±6÷‹üºš÷pøÆ¨Õ››ºûb vøE÷ ¶÷ æ÷ ø2ø}«tŸg‡‹ƒ‚Š†•®§®À¯ŸHh^OQW®dº¬¤£«û{«tŸg‚€‡‹ƒ‚Š…Œ•®§®À¯ŸHi^NQW®dº¬¤£«ûb vøÍö©÷ æ÷ ø%øİ¿h²\jrskl¢w¯•”‹”•‡Š‰iogVh•wÎ­¸ÈÄû{¿h²\jrskl¢w¯•”‹”•Œ†Š‰iogVh•wÎ­¸ÈÄûb„óø¹¨÷Mó«èø2ø›æ?Ì .EM9dœt©¥››¤™…˜}š}›‡’•©»ª»ÆºUGb}PuVoIy`€XŠ\•Öš©ÏàÀÍ¢½‹¼ûün¨t¢nnttnn¢t¨¨¢¢¨ü vøbwƒ÷rûßp ÷…øû'÷)|š}’|‹z}}zz”}÷.*ûBüĞ÷›K–Ó÷÷†XyWxXx|©Œ‹“¦”{_û{CGˆ{5 v÷pÎHÍ÷ÍĞø©÷pÎûn÷pI°ûqûoI÷oûpÍ÷pu¡øW–÷\š’‹÷š”ü}¦
ß
_÷ù
endstream
endobj
1 0 obj
<</OPM 1/Type/ExtGState>>
endobj
80 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
81 0 obj
<</OP false/OPM 0/op false>>
endobj
82 0 obj
<</A 83 0 R/Border[0 0 0]/Rect[243.612 9.0 285.357 16.0]/Subtype/Link/Type/Annot>>
endobj
83 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
74 0 obj
[84 0 R]
endobj
75 0 obj
<</Length 15161>>stream
1 g
/GS0 gs
0 783 0 0 re
f
0 0 0 0 k
/GS1 gs
50.5 36.5269 493 696.6661 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.007 Tc 0.007 Tw 10.5 0 0 10.5 50.5 726.0132 Tm
(thors concluded that there was no statistically significant)Tj
-0.02499 Tc 0.017 Tw 0 -1.23809 TD
[(change in QT)70 (c intervals from baseline, approximately 30%)]TJ
0.013 Tw 0 -1.2381 TD
(of the patients had noteworthy prolongation.)Tj
-0.024 Tc 0.02299 Tw 1 -1.22619 Td
[(In a prospective, open-label study)65 (, Straker et al. evaluat-)]TJ
-0.03101 Tc 0.01601 Tw -1 -1.22619 Td
[(e)-15 (d)-15 ( )-15 (t)-15 (h)-15 (e)-15 ( )-15 (e)-15 (f)5 (f)-15 (e)-15 (c)-15 (t)-15 (s)-15 ( )-15 (o)-15 (f)-15 ( )-15 (a)-15 (r)-15 (i)-15 (p)-15 (i)-15 (p)-15 (razole in the treatment of delirium in)]TJ
-0.015 Tc 0.00101 Tw 0 -1.22619 TD
(14 general medicine patients.)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 6 0 0 6 169.0108 664.6882 Tm
(7)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.00101 Tw 10.5 0 0 10.5 174.404 661.3882 Tm
(The mean age of the 6 men)Tj
-0.021 Tc 0.006 Tw -11.80038 -1.22619 Td
[(and 8 women was 70.9 \261)-220 (1)35 (1.3 years. Oral aripiprazole was)]TJ
-0.03 Tc 0.015 Tw T*
[(used, with a mean dose of 8.9 \261)-220 (3.5 mg per day)65 (. Changes in)]TJ
-0.024 Tc 0.009 Tw T*
(delirium rating scales were the primary outcome measures;)Tj
-0.015 Tc 0.061 Tw T*
[(QT)70 (c interval data were also assessed. Mean QT)70 (c interval)]TJ
-0.03999 Tc 0.017 Tw T*
[(length at baseline was 442 \261)-212 (44 msec. Follow-up ECGs were)]TJ
-0.015 Tc 0.02901 Tw 0 -1.22618 TD
(obtained in 10 of the 14 patients and revealed a mean de-)Tj
0.00999 Tw T*
[(crease of the QT)70 (c interval from 451 \261)-230 (50 to 434 \261)-229 (22 mil-)]TJ
-0.017 Tc 0.002 Tw 0 -1.22619 TD
[(liseconds. The authors mentioned that the QT)70 (c interval in-)]TJ
-0.035 Tc 0.02 Tw T*
[(creased in 3 patients; however)40 (, the degree of change was not)]TJ
-0.039 Tc 0.024 Tw T*
[(noted. While it was not the study\325)55 (s primary objective to eval-)]TJ
-0.01801 Tc 0.00301 Tw T*
(uate the cardiac safety of aripiprazole in delirious patients,)Tj
-0.028 Tc 0.013 Tw 0 -1.22618 TD
(there were no reports of TdP and aripiprazole demonstrated)Tj
-0.03999 Tc 0 -1.22619 TD
[(minimal ef)20 (fects on the QT)70 (c interval. )]TJ
-0.02499 Tc 0.022 Tw 1 -1.22619 Td
[(Given the lack of data associating aripiprazole with QT)70 (c)]TJ
-0.02299 Tc 0.02299 Tw -1 -1.22619 Td
(interval prolongation and the patient\325)Tj
-0.0229 Tc 14.05274 0 Td
(s)Tj
-0.02299 Tc 0.61603 0 Td
(response to quetiap)Tj
0 Tc 7.33174 0 Td
(-)Tj
-0.01401 Tc 0.013 Tw -22.00051 -1.2262 Td
(ine, aripiprazole was initiated for treatment of delirium in)Tj
-0.02499 Tc 0.004 Tw T*
[(our patient with schizophrenia. At the time of TdP)110 (, the only)]TJ
0 Tc 0.006 Tw T*
(other risk factor identified was concomitant famotidine.)Tj
-0.009 Tc 0.009 Tw T*
[(The prescribing infor)-25 (mation for famotidine states that, in)]TJ
-0.01601 Tc 0.01601 Tw T*
[(patients with renal impair)-25 (ment, QT)70 (c interval prolongation)]TJ
-0.00999 Tc 0.00999 Tw T*
[(occurs very rarely)65 (. Cases identified also indicate that sig-)]TJ
-0.01801 Tc 0.01801 Tw T*
[(nificant renal impair)-25 (ment is an important factor in famoti-)]TJ
-0.026 Tc 0.011 Tw T*
(dine-induced QT)Tj
-0.02631 Tc 6.35021 0 Td
(c)Tj
-0.026 Tc 0.65257 0 Td
(interval prolongation.)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0 Tw 6 0 0 6 209.0573 368.5632 Tm
(44,45)Tj
ET
BT
/T1_0 1 Tf
-0.026 Tc 10.5 0 0 10.5 224.2375 365.2632 Tm
(Finally)Tj
-0.02631 Tc 2.58434 0 Td
(,)Tj
-0.026 Tc 0.011 Tw 0.45859 0 Td
(in vitro)Tj
-0.01401 Tc 0.013 Tw -19.58936 -1.22619 Td
(and in vivo tests have concluded that famotidine does not)Tj
-0.015 Tc 0.015 Tw T*
[(af)20 (fect potassium channels responsible for cardiac repolar-)]TJ
-0.02499 Tc 0 Tw T*
(ization.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 6 0 0 6 79.6339 329.9382 Tm
(46)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.02499 Tw 10.5 0 0 10.5 87.9641 326.6382 Tm
(Given that the patient had an estimated creatinine)Tj
0 Tc 0.073 Tw -3.56801 -1.22619 Td
(clearance greater than 60 mL/min, the literature would)Tj
-0.02499 Tc 0 Tw T*
(suggest that famotidine was less of a risk, if at all, contribu-)Tj
0 Tc 0.005 Tw T*
[(tory in our case. Further)-25 (more, our patient was receiving)]TJ
0.073 Tw T*
(famotidine both before and after aripiprazole use, with)Tj
-0.02499 Tc 0.013 Tw T*
(documented QT)Tj
-0.0251 Tc 6.08739 0.00001 Td
(c)Tj
-0.02499 Tc 0.6563 0 Td
[(intervals within nor)-21.8 (mal limits. )]TJ
-0.01801 Tc 0.01801 Tw -5.7437 -1.2262 Td
(One additional consideration when evaluating the asso-)Tj
-0.02 Tc 0.02 Tw -1 -1.22619 Td
(ciation between aripiprazole administration and TdP is the)Tj
0 Tc 0 Tw T*
(nor)Tj
0.123 Tw 1.35767 0.00001 Td
[(malization of QT)70 (c interval upon withdrawal of the)]TJ
-0.009 Tc 0.009 Tw -1.35767 -1.2262 Td
(drug. After the occurrence of TdP and discontinuation of)Tj
-0.01601 Tc 0.01601 Tw T*
[(aripiprazole, the patient\325)55 (s QT)70 (c interval retur)-25 (ned to nor)-25 (mal)]TJ
-0.02499 Tc 0.021 Tw T*
[(over 14 days, which is possibly related to the 75)-25 (-hour half-)]TJ
-0.024 Tc 0.024 Tw T*
(life of the agent.)Tj
ET
BT
/T1_1 1 Tf
-0.022 Tc 0 Tw 6 0 0 6 115.5158 175.4381 Tm
(42)Tj
ET
BT
/T1_0 1 Tf
-0.024 Tc 0.024 Tw 10.5 0 0 10.5 123.8526 172.1381 Tm
(This would further suggest that aripipra-)Tj
-0.02499 Tc 0.021 Tw -6.98596 -1.22619 Td
[(zole was the precipitating factor for QT)70 (c interval prolonga-)]TJ
0.013 Tw T*
(tion and TdP in this case. )Tj
-0.015 Tc 0.015 Tw 1 -1.22619 Td
[(T)70 (o our knowledge, this is the first reported case of TdP)]TJ
-0.013 Tc 0.013 Tw -1 -1.22619 Td
(associated with aripiprazole therapy)Tj
-0.01331 Tc 13.90639 0.00001 Td
(.)Tj
-0.013 Tc 0.4866 0 Td
(Clinicians should be)Tj
-0.015 Tc 0.015 Tw -14.393 -1.2262 Td
[(aware that low-)-75 (dose aripiprazole may produce significant)]TJ
-0.00999 Tc 0.00999 Tw 0 -1.2262 TD
[(QT)70 (c interval prolongation and TdP in patients with mini-)]TJ
-0.024 Tc 0.024 Tw T*
(mal risk factors. Since aripiprazole may be selected for pa-)Tj
-0.022 Tc 0.022 Tw T*
[(tients with a history of QT)70 (c interval prolongation or a high)]TJ
-0.00301 Tc 0.00301 Tw T*
(baseline interval, more cardiac data are needed to assess)Tj
-0.02499 Tc 0.013 Tw T*
(the safety of the drug in this population.)Tj
ET
BT
/T1_2 1 Tf
0.007 Tc 0.007 Tw 8.5 0 0 8.5 309 726.999 Tm
(Sarah Nelson)Tj
ET
BT
/T1_3 1 Tf
0.0069 Tc 0 Tw 8 0 0 8 366.423 726.999 Tm
(P)Tj
0.007 Tc 0.007 Tw (harmD BCPS, Critical Care Clinical Pharmacist,)Tj
-0.00011 Tc -7.17787 -1.125 Td
(M)Tj
0 Tc -0.01401 Tw [(ayo Clinic, Rochester)55 (, MN)]TJ
ET
BT
/T1_2 1 Tf
-0.0231 Tc 0 Tw 8.5 0 0 8.5 309 706.999 Tm
(J)Tj
-0.02299 Tc -0.005 Tw (onathan G Leung)Tj
ET
BT
/T1_3 1 Tf
8 0 0 8 382.3974 706.999 Tm
[(PharmD BCPS BCPP)129 (, Psychiatric Clinical Phar)-1 (-)]TJ
0 Tc -0.01401 Tw -9.17467 -1.125 Td
(macist, Mayo Clinic, Rochester)Tj
ET
BT
/T1_2 1 Tf
0 Tw 8.5 0 0 8.5 309 686.999 Tm
(Correspondence:)Tj
ET
BT
/T1_3 1 Tf
-0.01401 Tw 8 0 0 8 381.4669 686.999 Tm
[(Dr)55 (. Nelson, nelson.sarah3@mayo.edu)]TJ
ET
BT
/T1_2 1 Tf
-0.03101 Tc -0.007 Tw 8.5 0 0 8.5 309 675.999 Tm
(Reprints/Online Access:)Tj
ET
BT
/T1_3 1 Tf
0 Tw 8 0 0 8 403.062 675.999 Tm
[(www)55 (.theannals.com/cgi/reprint/aph.1R387)]TJ
ET
BT
/T1_2 1 Tf
0 Tc -0.01401 Tw 8.5 0 0 8.5 309 660.999 Tm
(Conflict of interest:)Tj
ET
BT
/T1_3 1 Tf
8 0 0 8 388.7657 660.999 Tm
(Authors reported none)Tj
-9.97071 -1.87501 Td
(\251)Tj
-0.00999 Tc -0.01801 Tw 0.97688 0.00001 Td
(1967-2013 Harvey Whitney Books Co. All rights reserved. No part)Tj
0.00301 Tc 0.011 Tw -0.97688 -1.12501 Td
(of this document may be reproduced or transmitted in any form or)Tj
0.009 Tc 0.005 Tw 0 -1.125 TD
(by any means without prior written permission of Harvey Whitney)Tj
-0.017 Tc -0.011 Tw T*
(Books Co. For reprints of any article appearing in )Tj
ET
BT
/T1_4 1 Tf
8 0 1.70046 8 477.4647 618.9989 Tm
(The Annals)Tj
ET
BT
/T1_3 1 Tf
-0.01669 Tc 0 Tw 8 0 0 8 516.508 618.9989 Tm
(,)Tj
-0.017 Tc 0.51144 0 Td
(please)Tj
0 Tc -0.01401 Tw -26.44993 -1.125 Td
(contact 415sales@hwbooks.com)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0 Tw 10.5 0 0 10.5 309 581.999 Tm
(References)Tj
ET
BT
/T1_0 1 Tf
-0.009 Tc 0.009 Tw 8 0 0 8 312.9293 564.124 Tm
[(1.)-491 (Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for\)]TJ
-0.02499 Tc 0.005 Tw 1.19634 -1.23437 Td
(the sustained use of sedatives and analgesics in the critically ill adul\t. Crit)Tj
0.013 Tw 0 -1.23437 TD
[(Care Med 2002;30:1)35 (19)-25 (-)-125 (41. )]TJ
0 Tc 0.08701 Tw -1.1875 -1.35938 Td
[(2.)-500 (Skrobik YK, Ber)20 (geron N, Dumont M, Gottfried SB. Olanzapine vs)]TJ
-0.00101 Tc 0 Tw 1.1875 -1.23437 Td
(haloperidol: treating delirium in a critical care setting. Intensive Car\e)Tj
-0.02499 Tc 0.013 Tw 0 -1.23438 TD
[(Med 2004;30:444)-75 (-9. doi: 10.1007/s00134)-75 (-)-100 (003)-24 (-)-25 (21)35 (17-)-100 (0)]TJ
-0.017 Tc 0.017 Tw -1.204 -1.35938 Td
[(3.)-483 (Devlin JW)90 (, Roberts RJ, Fong)-1 ( JJ, et al. Ef)21 (ficacy and safety of quetiapine)]TJ
-0.02499 Tc 0.01199 Tw 1.204 -1.23438 Td
[(in critically ill patients with delirium: a prospective, multicenter)40 (, random-)]TJ
-0.01401 Tc 0.01401 Tw 0 -1.23437 TD
[(ized, double-blind, placebo-controlled pilot study)65 (. Crit Care Med 2010;)]TJ
-0.02499 Tc 0 Tw 0 -1.23438 TD
(38:419)Tj
0.013 Tw 2.65272 0 Td
[(-)-25 (27. doi: 10.1097/CCM.0b013e3181b9e302)]TJ
-0.022 Tc 0.022 Tw -3.86211 -1.35938 Td
[(4.)-478 (Girard TD, Pandharipande PP)110 (, Carson SS, et al. Feasibility)65 (, ef)20 (ficacy)65 (, and)]TJ
-0.01601 Tc 0.01601 Tw 1.20939 -1.23438 Td
(safety of antipsychotics for intensive care unit delirium: the MIND ran-\)Tj
-0.02499 Tc 0.013 Tw 0 -1.23437 TD
[(domized, placebo-controlled trial. Crit Care Med 2010;38:428)-25 (-)-25 (37. )]TJ
0 -1.23438 TD
(doi: 10.1097/CCM.0b013e3181c5871)Tj
0 Tc 0.089 Tw -1.1875 -1.35938 Td
[(5.)-500 (Boettger S, Friedlander M, Breitbart W)90 (, Passik S. Aripiprazole and)]TJ
-0.021 Tc 0.021 Tw 1.1875 -1.23438 Td
[(haloperidol in the treatment of delirium. Aust N Z J Psychiatry 201)35 (1;45:)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23437 TD
[(477-)-25 (82. doi: 10.3109/00048674.201)35 (1.54341)35 (1)]TJ
0 Tw -1.2125 -1.35938 Td
(6.)Tj
0.019 Tw 1.17499 0 Td
(Boettger S, Breitbart W)Tj
-0.0251 Tc 8.88832 0 Td
(.)Tj
-0.02499 Tc 0.46874 0 Td
(An open trial of aripiprazole for the treatment of)Tj
0.009 Tw -9.31955 -1.23438 Td
[(delirium in hospitalized cancer patients. Palliat Support Care 201)35 (1;9:351)50 (-)]TJ
0.013 Tw 0 -1.23438 TD
[(7. doi: 10.1017/S147895151)35 (1000368)]TJ
-0.004 Tc 0 Tw -1.19176 -1.35937 Td
(7.)Tj
0.004 Tw 1.23724 0 Td
[(Straker DA, Shapiro P)96.7 (A, Muskin PR. Aripiprazole in the treatment of)]TJ
-0.02499 Tc 0.013 Tw -0.04547 -1.23438 Td
(delirium. Psychosomatics 2006;47:385)Tj
0 Tw 14.73115 0 Td
(-91.)Tj
-0.024 Tc -15.9426 -1.35938 Td
(8.)Tj
0.024 Tw 1.17815 0 Td
(Alao AO, Moskowitz L. Aripiprazole and delirium. Ann Clin Psychiatry)Tj
-0.02499 Tc 0.013 Tw 0.0333 -1.23438 Td
(2006;18:267-9. doi: 10.1080/10401230600948506)Tj
-0.022 Tc 0.022 Tw -1.20958 -1.35938 Td
[(9.)-478 (Alao AO, Soderber)20 (g M, Pohl EL, Koss M. Aripiprazole in the treatment)]TJ
-0.02499 Tc 0.013 Tw 1.20958 -1.23437 Td
(of delirium. Int J Psychiatry Med 2005;35:429)Tj
0 Tw 17.55442 0 Td
[(-)-25 (33.)]TJ
0.011 Tw -19.24192 -1.35938 Td
[(10.)-475 (Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for)]TJ
0.013 Tw 1.6875 -1.23438 Td
[(the treatment of delirium. Psychosomatics 2004;45:297-)-25 (301.)]TJ
-0.019 Tc 0.019 Tw -1.6875 -1.35938 Td
[(1)35 (1.)-482 (Miyaji S, Y)100 (amamoto K, Hoshino S, Y)100 (amamoto H, Sakai Y)130 (, Miyaoka H.)]TJ
0 Tc 0.136 Tw 1.6875 -1.23437 Td
(Comparison of the risk of adverse events between risperidone and)Tj
-0.036 Tc 0.02 Tw T*
[(haloperidol in delirium patients. Psychiatry Clin Neurosci 2007;61:275)-24 (-)-26 (8)-1 (2)-1 (.)]TJ
-0.02499 Tc 0 Tw 0 -1.23437 TD
[(doi:10.1)35 (1)35 (1)35 (1/j.1440)-75 (-1819.2001.01655.x)]TJ
-0.009 Tc 0.009 Tw -1.6875 -1.35938 Td
[(12.)-491 (Kim SW)90 (, Y)100 (oo JA, Lee SY)131 (, et a)-1 (l. Risperidone versus olanzapine for the)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23437 Td
[(treatment of delirium. Hum Psychophar)-19 (macol 2010;25:298)]TJ
0 Tc 22.42262 0.00002 Td
(-)Tj
-0.02499 Tc 0 Tw [0.3 (302. )]TJ
0.013 Tw -22.42263 -1.23439 Td
(doi: 10.1002/hup.1)Tj
-0.06 Tc 0 Tw 7.11081 -0.00001 Td
[(11)-35 (7)]TJ
-0.019 Tc 0.019 Tw -8.79831 -1.35937 Td
[(13.)-481 (Mittal D, Jimerson MA, Neely EP)110 (, et al. Risperidone in the treatment of)]TJ
1.6875 -1.23437 Td
(delirium: resulting from a prospective open-label trial. J Clin Psychiat\ry)Tj
-0.02499 Tc 0 Tw T*
(2004;65:662-7. )Tj
-0.017 Tc 0.017 Tw -1.6875 -1.35938 Td
[(14.)-483 (Liu CY)130 (, Juang YY)130 (, Liang HY)131 (, Lin NC, Y)100 (eh EK. Ef)20 (ficacy of risperidone)]TJ
-0.013 Tc 0.013 Tw 1.6875 -1.23438 Td
(in treating the hyperactive symptoms of delirium. Int Clin Psychophar-)Tj
-0.02499 Tc T*
[(macol 2004;19:165)-25 (-)-25 (8.)]TJ
0 Tc 0 Tw -1.6875 -1.35938 Td
(15.)Tj
0.13 Tw 1.75 0.00001 Td
[(Grover S, Kumar V)130 (, Chakrabarti S. Comparative ef)20 (ficacy study of)]TJ
-0.009 Tc 0.009 Tw -0.0625 -1.23438 Td
(haloperidol, olanzapine, and risperidone in delirium. J Psychosom Res)Tj
-0.02499 Tc 0 Tw 0 -1.23438 TD
[(201)35 (1;71:277-)-25 (81.)]TJ
-0.00101 Tc 0.00101 Tw -1.6875 -1.35938 Td
[(16.)-499 (Horikawa N, Y)100 (amazaki T)75 (, Miyamoto K, et al. T)35 (reatment for delirium)]TJ
-0.024 Tc 0.024 Tw 1.6875 -1.23437 Td
(with risperidone: results of a prospective open trial with 10 patients. \Gen)Tj
-0.02499 Tc 0.013 Tw 0 -1.23437 TD
[(Hosp Psychiatry 2003;25:289)-25 (-92.)]TJ
-0.007 Tc 0.007 Tw -1.6875 -1.35938 Td
[(17.)-493 (Parellada E, Baeza I, de Pablo J, Martinez G. Risperidone in the treat-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23438 Td
[(ment of a patient with delirium. J Clin Psychiatry 2004;65:348)-25 (-53.)]TJ
0 Tc 0.006 Tw -1.6875 -1.35938 Td
[(18.)-500 (Lacasse H, Perreault MM, W)40 (illiamson DR. Systematic review of an-)]TJ
-0.022 Tc 0.022 Tw 1.6875 -1.23437 Td
(tipsychotics for the treatment of hospital-associated delirium in medica\l-)Tj
-0.02499 Tc 0.013 Tw T*
[(ly or sur)20 (gically ill patients. Ann Phar)-25 (macother 2006;40:1966)-25 (-73.)]TJ
ET
0 0 0 0 k
309 740.1929 234.5 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
8 0 0 8 333.0128 744.7228 Tm
[(T)90 (orsades de Pointes After Administration of Low-Dose Aripiprazole)]TJ
ET
0 0 0 0 k
157.5 15.444 386 13.08 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
10 0 0 10 260.0963 21.6856 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 393.2213 23.1856 Tm
(n)Tj
ET
BT
/T1_6 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 406.4024 21.6856 Tm
[(2013 February)55 (, V)110 (olume 47    )]TJ
ET
BT
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 516.9322 23.1856 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 10 0 0 10 530.1133 21.6856 Tm
[(e1)57 (1)]TJ
ET
0 0 0 0 k
50.5 16.524 79.5 11.669 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.02499 Tc 10 0 0 10 50.5 21.3551 Tm
(theannals.com)Tj
ET
BT
0 g
/GS2 gs
/T1_8 1 Tf
0 Tc 5 0 0 5 284.35733 11 Tm
( at UNIV CALGARY LIBRARY on May 25, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
36 0 obj
<</BaseFont/ITLCLN+Helvetica-Bold/Encoding 33 0 R/FirstChar 32/FontDescriptor 35 0 R/LastChar 117/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 0 0 722 722 722 722 667 0 778 0 278 556 0 611 833 722 778 0 0 722 667 611 722 667 0 0 667 0 0 0 0 0 0 0 556 0 556 611 556 333 611 611 278 0 0 278 0 611 611 611 0 389 556 333 611]>>
endobj
12 0 obj
<</BaseFont/QZOEKJ+Helvetica/Encoding 9 0 R/FirstChar 32/FontDescriptor 11 0 R/LastChar 169/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 278 333 278 278 556 556 556 556 556 556 556 556 556 556 278 278 0 0 0 0 1015 667 667 722 722 0 611 778 722 0 500 0 556 833 722 778 667 778 722 667 611 0 0 944 0 0 0 0 0 0 0 0 0 556 556 500 556 556 278 556 556 222 222 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>
endobj
40 0 obj
<</BaseFont/DXOVRD+Helvetica-Oblique/Encoding 37 0 R/FirstChar 32/FontDescriptor 39 0 R/LastChar 116/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 611 0 0 0 0 0 0 0 0 0 0 0 0 556 0 500 0 556 0 0 556 0 0 0 222 833 556 556 0 0 333 500 278]>>
endobj
37 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 46/period 65/A 80/P 84/T 97/a 99/c 101/e 104/h 108/l/m/n/o 114/r/s/t]/Type/Encoding>>
endobj
39 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-214 -224 1198 931]/FontFile3 38 0 R/FontName/DXOVRD+Helvetica-Oblique/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
38 0 obj
<</Length 1388/Length1 1388/Subtype/Type1C>>stream
  DXOVRD+Helvetica-Oblique   Eø øøøøû:ûtú|ú7
 ‹
 o
 ‹‹      ü  !¬  K €ˆ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki    " O  1 I B S N D P U F M T  5    < ~  Ã ı‰Â!sºëH]×çœ v÷dâø:w™ùù û˜ùaûû ıaîÖ÷d÷³Òûd!÷»ûr÷÷Ğ- vø^Û|wÌŞ8ä÷âôø€÷÷÷IÎûEZpM_‰ôÕ8üŸìä÷°÷ÀÌåÕ­`.ûÖüœ v÷ÂŞ÷İáí÷çîùø˜÷6Ûûû×ıaí÷Â÷u÷áá÷(‰6Y_+ûU÷÷Xé¼b;- vø_Û÷FwÌã÷âø÷÷÷
KÍûHbtLY‰÷œ3ıaã÷±÷ÂÊëĞªf:ûé-|Ô[v÷‰Í÷8Ô¯äLÛ÷…ã6àµø¤Ë‡~ƒŠ„vƒ”¡÷Áæ@ÂûûHTû
„ÛÑ•°©ÙÖ·kSi{wl‡û$y¹$~SQ.0ÍOí×Ã¤ÇÄöQ‘¤tÃ–”¡ºû%÷HK>Q5Qf«¿À¯©Ø”÷˜†Š³ŸûÑ vøPé|wØİ9ãğ÷ßøPæ~„Œ‡QamB]‰ğã9üŸèã÷ÄÜÃÆÙ÷K vø_Ú|wÌŞ8ã÷qã÷nãöù”÷ş÷KÎ%Lp|EJÅo^¦IGYoNc‰öÕ8üŸîã÷±ôÁĞß¾«fOûşã÷ÓÙÁÉÎÌ«c:ûæû*{Øø"Ú©é÷ à7ßèøq÷L7<y]_I1ZÒ÷÷ÂÕçğÏ±h>šà÷}GÌûû)*ûû?û8ç ÷"÷ÛÖ÷™-}×ø$×®æ÷Äæø÷š÷7'÷û#û#'ûû7û8îû÷$÷$î÷÷80ûP=..PÙ÷÷ÆÙèèÆ=ûü„×øÕßã÷•Ğmez—¨÷çßÕ7÷&3û&EAÑûì?¬gĞœ™Œ‘³-|×÷@Ñ÷/Û³è÷´â8æôø˜÷}÷V:÷û%û1.û ûKû6ç'÷*ø÷ØÈ÷
§4J{YeC.WÃ÷†ô÷¸Ñû¸ì”ÇÅİï°@;ü@ vùawÎã÷/ùa3ıaû*|Ö÷2ÙVÖ÷$×«ßGß÷yàDãÕøc÷2Ôc± ¦ö4¡<Ÿy˜‹±·µ¨ÊÜ±pNà÷ ‚FÃûû=J%I³aİwÙğrŞv }‹dW]k@2d©Ù7T’qp«\Óoæ‹÷‹ŞĞ‹óü‹õâó÷Sõ#!d vùà÷•ëøçùàüÙ6÷‡ıëùu¡øŸš÷)›™Ÿ÷¡–ü}š×
ã
_÷ªù
endstream
endobj
9 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 64/at/A/B/C/D 70/F/G/H 74/J 76/L/M/N/O/P/Q/R/S/T 87/W 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 169/copyright]/Type/Encoding>>
endobj
11 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-166 -224 1000 931]/FontFile3 10 0 R/FontName/QZOEKJ+Helvetica/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
10 0 obj
<</Length 5282/Length1 5282/Subtype/Type1C>>stream
  QZOEKJ+Helvetica   @ø øøøøû:ûtú|ú7
 ‹‹
 ‹‹   ó   ï  v¬   €ˆ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki  @  ) 4 B S I  / F M T P O  + U ( - V H 5 E D J C G Q 	 1 
 X [  "    Z N L W ' R  2    % K $    0   3  Y ª  8 # ! . B   1 ²>w±´ß<QËTƒ·èRi§)F¥÷s¬I‹Ç,<v«			i	È	û
#
F
¥
ìX|ÓM’È%^—´}˜úz·IÁq(ƒÓ v÷áâ÷½wØì*íø
ìôùùa*û½ü÷½*ıaìí÷áø
ûáœxŞ÷‹Ù`å÷nŞ¼æGè÷êæCèÕøÿ÷YïQÏ#£öûaºQ˜n¬‹½ÖÊºğ÷ÇZ*”æ÷/€3ÕûBû2,7û3¿SñsÙ÷&h÷
o¯p‹N4L_ûûDÆöˆ0ŒD•e©dG¿Ùi÷ ÷KöÛ÷-|Ô[v÷‰Í÷8Ô¯äLÛ÷…ã6àµø¤Ë‡~ƒŠ„vƒ”¡÷Áæ@ÂûûHTû
„ÛÑ•°©ÙÖ·kSi{wl‡û$y¹$~SQ.0ÍOí×Ã¤ÇÄöQ‘¤tÃ–”¡ºû%÷HK>Q5Qf«¿À¯©Ø”÷˜†Š³ŸûÑ vøPé|wØİ9ãğ÷ßøPæ~„Œ‡QamB]‰ğã9üŸèã÷ÄÜÃÆÙ- vø_Û÷FwÌã÷âø÷÷÷
KÍûHbtLY‰÷œ3ıaã÷±÷ÂÊëĞªf:ûéüÓ vùaw×èøêùùa,ü×‰ûúø×ûıaèøØøüØ-|×÷@Ñ÷/Û³è÷´â8æôø˜÷}÷V:÷û%û1.û ûKû6ç'÷*ø÷ØÈ÷
§4J{YeC.WÃ÷†ô÷¸Ñû¸ì”ÇÅİï°@;ü@ vùawÎã÷/ùa3ıaû*|Ö÷2ÙVÖ÷$×«ßGß÷yàDãÕøc÷2Ôc± ¦ö4¡<Ÿy˜‹±·µ¨ÊÜ±pNà÷ ‚FÃûû=J%I³aİwÙğrŞv }‹dW]k@2d©Ù7T’qp«\Óoæ‹÷‹ŞĞ‹ó-}×ø$×®æ÷Äæø÷š÷7'÷û#û#'ûû7û8îû÷$÷$î÷÷80ûP=..PÙ÷÷ÆÙèèÆ=û- vø^Û|wÌŞ8ä÷âôø€÷÷÷IÎûEZpM_‰ôÕ8üŸìä÷°÷ÀÌåÕ­`.ûÖü‹õ6vâóX¾Ğ÷S“íà#!ĞÀàŠHsc]Ó›«»æû*xİù"wœå÷sìø?÷VøŸ*ü¥7fb>Bg²Ú½1DûØG÷÷ÖÙ÷ü„×øÕßã÷•Ğmez—¨÷çßÕ7÷&3û&EAÑûì?¬gĞœ™Œ‘³÷xŞ`v÷ÁŞ÷Ÿà»ïøeå|ùSøûÎ8÷tˆ@gqfüPcJm8û09ñ÷V÷Eé÷÷'÷ ĞY&«è÷(oûãû7ûbûû,ûûo÷û)÷TöØ®ØÉ|£.-‹áùw×ìø¬áûÿù*ıa-|×cvøŸwÏâ÷‰ã8Şôø|øŸø3û´ TH2Hi²×÷ï4ü%ÉOöÛ´¢Ñ¸ô=-ûnÓ÷×ø!Û|w³æ@ã÷Ÿã7ß9İÔ€ø‡¶øt9@ù ‰Ì^^¤Hû4"û0ûDäû÷Òµ À«ö uûcZûHg¤Ä}3"œÍZ÷÷7Õİ÷Gù 7÷bûWH/5UØ÷÷»Îçé½Cûd vùà÷•ëøçùàüÙ6÷‡ıëù-|×cvø_Ù÷Hw®å÷±ã4â:Üyø†ùaú4û¡‰Î[d¡Eû7&û5ûEäû÷!Ï»§Å­yDü„÷‰ûTD24UØ÷÷ºËêæ¿>ûû*{Øø"Ú©é÷ à7ßèøq÷L7<y]_I1ZÒ÷÷ÂÕçğÏ±h>šà÷}GÌûû)*ûû?û8ç ÷"÷ÛÖ÷™ü@ vøŸw÷íÎã÷/øÿí3)ãüÿøŸ3üŸ-{Øcvø`Ù÷GwÅã3ß÷±åzø™÷¨÷24óûMZqTc‰÷˜3ıaŞÌöN¸¯wÎ÷å÷÷D1ƒûW?13TÒ÷÷½×æê¼Iûü vøUÕ÷awßã÷˜øUÕ3Ì¶›°“”Š‰ÚŒw€Œ‚/_f=1EAÑüUãøU-ûLv÷R×ø#Ú{wÅŞ8ã3ß÷±åéø™÷¨÷24ôûH^qL`‰ùÔ8ılåã÷˜Wµ®yÈ÷#ã÷÷H1…ûX?0ã2UĞ÷÷!¼Õçê¼JûûÑûMvú>wÏè÷¿ûb<÷2P÷÷J÷D³÷ë÷;OûûB]ûû=ûVÑûòû0œ v÷ÂŞ÷İáí÷çîùø˜÷6Ûûû×ıaí÷Â÷u÷áá÷(‰6Y_+ûU÷÷Xé¼b;ûÑûNvú>w÷@è÷÷÷VE÷$÷0QÚû2ÆûûJûDcû+û;Ç÷÷B¹÷÷=Ó vøŸw›ùIùYøŸ4 ü.‰&ø.)&ü.‰'ø.,÷+üŸåñø)ôü)æû*‹ÓøÕªøIøhÓûÕ÷ÍøÕü)A÷¶ûÎüFü‹õâó÷Sõ#!œ v÷dâø:w™ùù û˜ùaûû ıaîÖ÷d÷³Òûd!÷»ûr÷÷Ğ- v÷>×ø]w÷ßãø÷>×%ø]BûÕüR4÷Æû>ã÷>3×ûu÷t÷ÔŒ-‹İø±Ú¥î:â÷¯çèøİü˜Ë»³Æ«Ô³ïÂã¼÷÷3ŞûØû3?$û)â÷‘¸ÁåàÄW=Dmk&Q/VèûFc5…ûûÑ v÷{å·÷ˆ÷´÷{åûˆ1û*ûjÚù&w–øqø|øŸ+û!ü?‰ûø?(÷Vü¬bû‚d‹v|‘v<…›—ˆœò› ÷_Øï÷œ–Ş÷‚÷K vø_Ú|wÌŞ8ã÷qã÷nãöù”÷ş÷KÎ%Lp|EJÅo^¦IGYoNc‰öÕ8üŸîã÷±ôÁĞß¾«fOûşã÷ÓÙÁÉÎÌ«c:ûæû* vøŸw÷jwÎàø‰ûh÷Û÷\÷Xûûvûqø36ıaà÷ZÔÍ÷7ûœû* vøŸw“øwøøŸ+û(ü=‰Šûø>'÷RüŸèd v÷Ùá÷pááìøÚùáü„ıaì÷Ù÷ôáûô÷p-ûNv÷T×ø"Ú|w®æ÷­â7ß8ŞÙø‚ûcùn8A‰üÉa\¦Gû4"û1ûGãû÷!È³Ÿ¼³û™úøYûUF14VØ÷÷ºÍçé¾Aû-wÛøÇÚ°è÷ºèø™÷é÷}6÷û/û/6ûû}ûzâû÷-÷-â÷÷z.ûKX)++Xí÷K÷O½êìì½+ûN÷xâøÜà²îø‰îùv÷û÷uû!÷-ûdûeû!û-ûuûv÷ û,÷fÓÃš¬Ã÷6¼Å)ÖÑÖ­è‹÷(/o>WU1ÑZOÕRa{q†e‹û(%÷
÷A÷Dï÷	÷+÷*ïû	ûD- vø†Ò÷w÷œêğø†÷7ü†êùREp$qxû€-x×÷ĞÚ÷*á«å÷½èø”÷x÷(ëûTfk^ª÷V÷½áûÿWüÖ†µ¼®À‹æÌK1*LJ/;\²Ù|1ûœ×K÷÷1ìé÷--xÚ÷œÔ÷wÚ­ç÷ªåIéôø÷bŞi»8­øÃ ¬¿Î÷6Õûû(FDû3ƒá÷ “²¶ãİ½`DAYd,~…‹z?Œ›“‹ô÷Âc39MU+*`¹÷‡/û6™ÓC÷(÷/îã÷Ó‹İø½İÜíøîù5ø÷gû÷ûJû·ıa÷³÷R÷÷÷z(…ûA< ûûOø½÷I÷5Àûûü@ûeÙù"w÷íÎã÷/øÿí3)ãıLøì3üâUTyA‡œ‹šè´´æÓwáøİà·îøHç5éèù;÷œ-ûqCHûû&8÷÷R÷Gçö÷+ğïÏV*¤ç÷*s!àû7ûaûû%ûxû‚÷û%÷\è÷?÷	õ÷F¤ü vø/õâóX¾Ğ÷Sø/õà#!óü'í#!ĞÀàŠHsc]Ó›«»æ- vøíá÷êøøöØüy5ø@1W:UûOûl/}#ê­÷4¢ÒÁ÷ Ä÷ÀÚĞØü‹õ÷Åõâó÷Sø/õ#!óü/õ#!÷xâøÜà²îø‰îùv÷û÷uû!÷-ûdûdû"û-ûuûv÷ û,÷f÷e÷ ÷,÷v(ûA%û
û(û)%÷
÷A÷Eï÷÷+÷*ïû	ûD-xÔ÷IÚ÷ËÙµå9â÷¦ñ4âòø•ø÷k7÷û6û1+û%ûà2÷ÙÁ¦Ä®‰nûX`H)‹êEa´Õ„4û”ÔI÷ÖÆ¨Åµ½Î¨÷÷ô%í#XR.6YÁçñ¿ÊßâÃP0üvù‡wz÷Ì÷»ùtIûŠı‡ÎÓ v÷ÇŞ÷ŠÜãëøîù>›oš…—‰¸…÷‡×y©K§Ö¹¤¶‹à‹÷6Ğû*‹ûßıaë÷Ç÷æ®i.ûŒ}˜R‚ø™6[a*ûv÷Š÷‡Ş¸a>-xÚ÷¢×÷oÙ±èEæ÷ŒæGèêø˜÷`ÙhÀ;²ìË¬¥´Î÷5Õûû7?ûI¨aÍmò5ck[/ûî4÷!÷$éã÷ìû÷ÑHV[BEW»ÌÌ¹´ÑÜ¾cKò¢ûÚ5XZ1.QÁâ×ÇÀàåÄV9û* vøŸw˜ørøûL÷ ÷E÷“û ûûMû÷Mû÷Bû“ûKû ÷÷÷Y÷ûYâxÊßÎ÷àÌŞÉ}ÖíØ÷œÏöÖù‚÷û÷eû?÷=ûgûgû?û=ûeûe÷?û=÷g÷g÷?÷=÷e@ûBûû!û>û>û÷!÷B÷C÷÷!÷>÷>÷û!ûC EGM{dkM6MÑìğÃËâÈ²mM ÎôuM¿"û3.ûûè)÷éÊÂõ§-xÚ÷ÉÚ÷EÚ±ä2ò÷§àAåòø™÷q÷1èû@VpOdˆ•÷?Çæñ‹ìË³fC˜à†Ç~«i­e²Q¢R‹û5‹*û#‹û‹ûváû÷7‹ê÷ìñ÷1†0RJ94OËççÄÈàãÃP-÷º vùaw›ú"ú2ùa ûüÛ‰û4øÛ"û6üÛ‰ûøÛ#÷Oıağ÷:øçŒ÷7üèñœ‹Ş÷Ù÷rİÔì÷ØëMëøù÷làg»-±Í­©»Ğö:ÓûûÎıa÷Êô÷%ëá÷øû÷Ë?Ye(ûC÷r÷Cï¼gCô­ûÍ7U\*ûc÷÷R÷Åb;øxÉèÌJÔ÷¸ÓñÈ÷'Ô×Şø:Ìßùöø>÷Cû*÷ûVûeû:û:ûdûk÷:û:÷l÷÷Î÷ÊI@H8d/ûBû÷÷C÷K÷÷÷A÷3÷ûû$ FûCyŠšš¤§éÈ÷cGwMlÄj W‹û$ûû,5ÍAØ¶¬˜½»a v±®À¢¬´ÒÆ±İèÿû“y*>%A[j³ÄìÕíÔ¹²`Y÷K vùawÔè.æøŠé/çäùŒùaûû_üñ‰ûaøñûıaèø<ÔÇ‰Æ‹Çè÷_üïë÷]øğäèŠû	Šº;‹‹‹üZu¡øŸš÷)›™Ÿ÷¡–ü}š×
ã
_÷ªù
endstream
endobj
33 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 47/slash 58/colon 65/A/B/C/D/E 71/G 73/I/J 76/L/M/N/O 82/R/S/T/U/V 89/Y 97/a 99/c/d/e/f/g/h/i 108/l 110/n/o/p 114/r/s/t/u]/Type/Encoding>>
endobj
35 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262176/FontBBox[-170 -227 1001 963]/FontFile3 34 0 R/FontName/ITLCLN+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
34 0 obj
<</Length 2993/Length1 2993/Subtype/Type1C>>stream
  ITLCLN+Helvetica-Bold   @ø øøøøû>ûwú}úW
 ‹‹
 ‹‹      Q²  Š €•002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki  $  0 # + & $ 5 * 7  " 4 6 . 3 : % / - B T F  Q P S U J D V O I M ( H E  G &   T Î2„¦½çIÖL±İ$SnîXº½(o´ğf­õ<S¹	2	”	±	é÷x÷øŠ÷·ùFùr÷ú÷mû÷6ûvûuûû4ûoûn÷	û3÷x÷t÷÷4÷mû*Œû0A,ûûAê÷0÷/Öë÷÷Ö+û/Ó‹÷÷U÷÷0÷×÷$÷®÷#û÷)ôù0÷màmº:±øÊ®¤´Î÷5Óûûğıa÷ÅŞÈ•­ôÏ±´ÑÛøû:÷ÁXdmGûC÷0÷?×®tWôœûºKafCûM÷U÷SÏ³iQ-y÷øúw¡÷÷A÷*øw÷dø‘û*ü‘?snNKs±ò¦ûlûOÌD÷A÷'×Ø÷)œ‹÷÷O÷÷+÷×÷'ù ÷ü!÷O÷ğ÷ûğ÷+ø÷ü¢ıaÓx÷øƒ÷·ùù?÷‰û)*n_f6ûHç÷,÷4Íæ÷
Şµi1§÷(÷-~ûğûAû]ûû'û|û|÷û$÷^÷;öæ÷A°d vøã÷÷z÷+øèøã÷üÚû÷lüã÷+øãü vùawË÷*÷jùaû*ıaœ vùawùùùaû/û0ü³‰Šû.ø´û4÷†ıa÷#ûÑ‹÷%÷r÷%ç÷*÷†ø÷%û*û%÷*ü÷%û*û%Ó v÷'÷øQwŸù;ùOû‘ùaûAû‘ıa÷1½÷'÷¹û'3÷¤ûLç÷°œw÷÷I÷$÷'÷6÷²÷"û÷÷¥÷#û÷%Õù	÷lòSÃû¬öûC·S™v ‹´À¼¬×æºhB•÷#÷$„ âû;ûA&8û"û*õo÷nÙØyîtªv‹^NYl&,Z°Ùƒû"C™d±a¿Såk÷‹÷@‹÷ç‹÷$Óx÷øöwÓøÖù÷øgû,üm/[^*;[Âåøeû-üpû7õ*÷F÷Tñè÷D÷K vùawĞ÷ ø4÷ùùaûlûüÉˆûøÉûoıa÷ øì÷üì÷(÷øìüìÓ v÷®÷÷T÷×÷(÷¸÷(ù9s”„À÷H€©:¯Õ©¯Äß÷3ÚûûÿŒıa÷'÷®÷/îšyû
ŒFo˜Zø†Ign:ûC÷T÷OÎ±hMœ vùawšùùùaû=û!ûËû*÷ËûD÷ŒüSû¢÷+÷¡Ó‹÷øi÷×÷'÷È÷,ù?ø÷n'÷ûSûĞıa÷Ë÷J÷÷%÷{û,û(M0'û&øi÷$÷À@û/Ó vùawĞ÷ ÷Ä÷ ù!ùaû üˆ‰û±øˆû1ıa÷ ø”÷¸ü”d‹÷øßw×øøÚ÷ûøøßû*ıa-}ïJv÷zÜ÷÷¨÷÷Q÷|ø¡ u’‚£¿÷´ë;Åûû0FUû€÷½§£ÀÊ¨x`t|}i†ûx${XR‹*ü.ËMëÓ²ÆÉ|Œq”püz÷SRS[K`q¤²»¡Ò˜Ğ˜ˆŠ©œ-}õ÷ğõ©÷#û÷û÷÷a÷ Ôøš÷9÷dûá?‹ê©«ÀÇ¨uZ‘÷÷„;Åû-û;D ûX÷İÊ‹3ggxVÌ=h¢Âˆäû#ûëE÷0÷#æĞ÷-}÷÷æ÷÷¢÷#û#÷ ÷p÷#ôø¢÷x¤÷P2ôû5û4.%ûDûIç&÷9÷ÚÂ÷¯û#cyny\ìAdµä„ô÷pæûmÚ˜«¬ÊÊ¯f@•üdûNv÷U÷÷Ù÷{wÉ÷û÷!÷{÷#êøÕ÷¤÷82÷ûAcsF^‰úØûıvæ÷!÷¦Œ­R¹rĞ‹÷á÷÷Dû#‚)^KEê?\Æé÷´ÆÙÖ·O$d}÷	÷Ù÷
­÷#÷•÷#øÕ÷÷?!÷û9û:!ûû?ûAó ÷<÷;ó÷ ÷@û# _S76_Ãöô¸ÄßŞ¸R"û™ vø(÷"|wË÷û÷ ğøø%÷"†‹Jgp<_‰ğæûü§è÷ ÷¨ß··ß–”Š‰ŸûÑ…õ÷ßïİ÷ ÷Èˆõ‰|„Š^„‘±÷³áï5÷%û û%C'ÓûÕ7³kò™Œ«ü vø§wŞ÷Ğ÷ ÷eøæ÷û û÷ üæø§û ü§-}÷÷Û÷
­÷$÷`÷!øŸ÷Vû!KjnSHgÁ÷õ³ÅÕº©pP˜÷!÷ƒ+Ôûû71$ûOû?å(÷/÷åØ÷d}÷
8vø§wÍ÷ ÷[÷û÷ôø³ø§øûûÇB`\IOm¬Ì÷İû ûñûÍC÷Ö¾§È¯ô@d vø?÷|wÌ÷û÷ ÷]÷ôø´ø÷DÏûC_rH`‰ôØûü§ì÷ ÷ÄØµ¹ÑÇ¨iEû×d vø@÷÷>wÌ÷û÷ ÷]÷ôøµø÷CÑûCVnUoˆ÷‘ûıaì÷ ÷Åß³²ÕÆ§jCû×ü vùawĞ÷ ÷eùaû ıa÷x÷4v÷÷÷u÷ø×÷xù[øû½û÷9øû oQY*ûAç÷0÷4Ùì÷×Æ_B¡÷(÷)xûæûCûiûû(ûzûv÷û+÷YíÌ«ÙÈx™0dûmõ÷ ÷
÷É÷|w³÷#÷z÷û÷Úø¼¨øŠû<‰üËmX©Dû4!û<û?â#÷!Ğ´£Ä«‡L4hh>Kt˜´û,#—ŞS÷'÷’÷.çû÷„*eR:G`Çéê¶ÇÎ×·J1d}÷;vø<÷÷?w­÷$÷|÷û÷zø¸ùaüûû“‰Ê^d Dû5û û;û@äû÷Ï¾¦Á®zHú÷˜&^Q=E^ÊìóµÆÖÚµR üvùˆwj÷ë÷Êùuû	ûvıˆ÷ûÑ vøEíÜ÷á÷ ÷ÑøEí0 ¿‘“µ²÷h€‹q#XZ%_?)×üE÷ øEwŸø§š÷,—’Ÿ˜‹÷£—ü|‹õ
÷ Œ
_÷ªù
endstream
endobj
76 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
77 0 obj
<</OP false/OPM 0/op false>>
endobj
84 0 obj
<</A 85 0 R/Border[0 0 0]/Rect[243.612 9.0 285.357 16.0]/Subtype/Link/Type/Annot>>
endobj
85 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
70 0 obj
[86 0 R]
endobj
71 0 obj
<</Length 13797>>stream
1 g
/GS0 gs
0 783 0 0 re
f
0 0 0 0 k
/GS1 gs
50.5 36.5269 493 696.6661 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01801 Tc 0.01801 Tw 10.5 0 0 10.5 61 726.0132 Tm
(Careful consideration must be given to the potential for)Tj
-0.02361 Tc -1 -1.23095 Td
(an)Tj
-0.024 Tc 0.024 Tw 1.14663 -0.00001 Td
[(antipsychotic to prolong the QT)70 (c interval, since critical-)]TJ
-0.02299 Tc 0.02299 Tw -1.14663 -1.23095 Td
(ly ill patients may have prolongation prior to antipsychotic)Tj
-0.00011 Tc 0 -1.23096 TD
(i)Tj
0 Tc 0.08099 Tw (nitiation from factors such as other medications, elec-)Tj
0.004 Tw T*
[(trolyte abnor)-25 (malities, and concurrent disease states.)]TJ
ET
BT
/T1_1 1 Tf
0.002 Tc 0 Tw 6 0 0 6 267.5877 677.6132 Tm
(24)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 276.2558 674.313 Tm
(In)Tj
-0.01601 Tc 0.01601 Tw -21.50055 -1.23095 Td
(2007, the Food and Drug Administration \(FDA\) strength-)Tj
0 Tc 0.01801 Tw 0 -1.23095 TD
[(ened war)-25 (nings regarding QT)70 (c interval prolongation and)]TJ
-0.005 Tc 0.005 Tw T*
(TdP with use of intravenous haloperidol, recommending)Tj
-0.013 Tc 0.013 Tw T*
(continuous electrocardiograph \(ECG\) monitoring with its)Tj
-0.015 Tc 0 Tw T*
(use.)Tj
ET
BT
/T1_1 1 Tf
-0.013 Tc 6 0 0 6 66.5066 612.9881 Tm
(25)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 74.9567 609.688 Tm
[(This war)-25 (ning did not apply to oral haloperidol, as it)]TJ
-0.01801 Tc 0.01801 Tw -2.32921 -1.23095 Td
[(has similar potential for prolonging the QT)70 (c interval com-)]TJ
0 Tc 0.134 Tw T*
(pared with risperidone and olanzapine.)Tj
ET
BT
/T1_1 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 219.1058 587.1381 Tm
(26,27)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.134 Tw 10.5 0 0 10.5 236.6402 583.8381 Tm
(Among the)Tj
-0.019 Tc 0.019 Tw -17.72764 -1.23095 Td
(SGAs, ziprasidone has demonstrated the greatest potential)Tj
0 Tc 0.157 Tw T*
[(to prolong the QT)70 (c interval.)]TJ
ET
BT
/T1_1 1 Tf
0.002 Tc 0 Tw 6 0 0 6 173.8619 561.2881 Tm
(27)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.157 Tw 10.5 0 0 10.5 184.1358 557.9881 Tm
(The FDA also recently)Tj
-0.019 Tc 0.019 Tw -12.72722 -1.23095 Td
[(strengthened the war)-25 (ning of QT)70 (c interval prolongation as-)]TJ
-0.02499 Tc 0.011 Tw T*
(sociated with quetiapine use.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 164.5342 535.438 Tm
(28)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.011 Tw 10.5 0 0 10.5 172.7154 532.1381 Tm
[(Conversely)65 (, aripiprazole has)]TJ
0 Tc -11.63956 -1.23095 Td
[(been shown to have minimal ef)20 (fect on the QT)70 (c interval,)]TJ
0.00101 Tw T*
[(with no reported cases of TdP)110 (.)]TJ
ET
BT
/T1_1 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 177.672 509.5881 Tm
[(2)-1 (9)-24 (-38)]TJ
ET
BT
/T1_0 1 Tf
0 Tc 0.00101 Tw 10.5 0 0 10.5 194.4518 506.2881 Tm
[(However)40 (, we report a)]TJ
-0.01801 Tc 0.01801 Tw -13.7097 -1.23095 Td
(case of nonfatal TdP associated with the administration of)Tj
-0.02499 Tc 0.013 Tw T*
(aripiprazole in a patient with minimal risk factors. )Tj
ET
BT
/T1_2 1 Tf
0.011 Tw 10.5 0 0 10.5 50.5 452.5131 Tm
(Case Report)Tj
ET
BT
/T1_0 1 Tf
-0.00011 Tc 0 Tw 10.5 0 0 10.5 61 431.5881 Tm
(A)Tj
0 Tc 0.97201 0 Td
(42-year)Tj
-0.015 Tc 3.03335 0.00001 Td
[(-)-90 (old white male with schizophrenia, diabetes)]TJ
-0.026 Tc 0.011 Tw -5.00536 -1.23096 Td
(mellitus, hypertension, and previous stroke presented to the)Tj
-0.039 Tc 0.024 Tw T*
[(emer)20 (gency department following 2 days of fever)40 (, chills, diar-)]TJ
T*
(rhea, and altered mental status. He was admitted to the medi-)Tj
-0.03999 Tc 0.008 Tw T*
(cal ICU for the treatment of sepsis. His ICU course was com-)Tj
-0.019 Tc 0.004 Tw T*
(plicated by the development of severe sepsis, renal failure,)Tj
-0.015 Tc 0.12601 Tw T*
[(adrenal insuf)20 (ficiency)65 (, and acute respiratory distress syn-)]TJ
-0.03999 Tc 0 Tw T*
(drome.)Tj
-0.02499 Tc 0.01401 Tw 1 -1.23095 Td
(One we)Tj
-0.03999 Tc [0.4 (ek into the hospital course, the patient was exhibit)]TJ
0 Tc 21.00056 0.00001 Td
(-)Tj
-0.02499 Tc 0.00999 Tw -22.00056 -1.23096 Td
(ing symptoms thought to be related to hypoactive delirium,)Tj
-0.02 Tc 0.005 Tw T*
(schizophrenia, or both. The dose of quetiapine used before)Tj
-0.02299 Tc 0.008 Tw T*
(admission \(400 mg by mouth at bedtime\) was restarted but)Tj
-0.035 Tc 0.02 Tw T*
[(discontinued after 1 dose when the QT)70 (c interval was discov-)]TJ
-0.01601 Tc 0.00101 Tw T*
(ered to be 644 milliseconds. The only prior ECG obtained)Tj
-0.037 Tc 0.022 Tw T*
[(was upon arrival at the emer)21.8 (gency department 7 days earlier)]TJ
0 Tc 22.08325 0.00002 Td
(,)Tj
-0.03999 Tc 0.02299 Tw -22.08325 -1.23098 Td
[(which revealed an interval of 528 milliseconds. T)70 (wenty-three)]TJ
-0.026 Tc 0.011 Tw T*
(days after quetiapine administration and at resolution of the)Tj
-0.015 Tc 0 Tw 0 -1.23096 TD
(patient\325)Tj
-0.01511 Tc 2.87878 0.00001 Td
(s)Tj
-0.015 Tc 0.019 Tw 0.62794 0 Td
[(acute illness, a new baseline QT)70 (c interval of 414)]TJ
0.04201 Tw -3.50672 -1.23095 Td
(milliseconds was obtained. Given the significant changes)Tj
0 Tw 0 -1.23095 TD
(with quetiapine, aripiprazole was initiated because of data)Tj
-0.033 Tc 0.01801 Tw T*
[(supporting its minimal ef)20 (fect on the QT)70 (c interval. Following)]TJ
-0.01711 Tc T*
(5)Tj
-0.017 Tc 0.002 Tw 0.71787 0 Td
[(days of aripiprazole 2.5 mg orally once daily)65 (, the patient)]TJ
-0.028 Tc 0.013 Tw -0.71787 -1.23095 Td
[(had a cardiac arrest due to TdP)110 (, identified by an ECG. Min-)]TJ
-0.015 Tc 0 Tw T*
[(utes prior to the event, an ECG recorded a QT)70 (c interval of)]TJ
-0.02901 Tc 0.01401 Tw T*
(624 milliseconds. The patient received cardiopulmonary re)Tj
0 Tc 22.00041 0.00001 Td
(-)Tj
-0.03999 Tc 0.002 Tw -22.0004 -1.231 Td
(suscitation for 30 seconds, 1 shock of 200 Joules, and magne)Tj
0 Tc 22.00056 0.00001 Td
(-)Tj
-0.015 Tc 0.168 Tw -22.0006 -1.231 Td
[(sium sulfate 4 g given intravenous push. Nor)-21.2 (mal sinus)]TJ
-0.03999 Tc 0.013 Tw 0.00002 -1.23099 Td
(rhythm was restored and aripiprazole was discontinued. )Tj
0 Tc 0.05299 Tw 1 -1.2381 Td
(The only additional risk factor present at the time of)Tj
-0.022 Tc 0.022 Tw -1 -1.2381 Td
[(TdP was concomitant intravenous famotidine 20 mg daily)65 (.)]TJ
0 Tc 0.27901 Tw 0 -1.2381 TD
(Relevant laboratory findings included potassium 3.8)Tj
0.00101 Tw 24.61905 64.99049 Td
(mEq/L, magnesium 1.5 mg/dL, and calcium 8.8 mg/dL.)Tj
-0.008 Tc 0.008 Tw 0 -1.23809 TD
[(Additionally)65 (, a cardiac catheterization conducted the fol-)]TJ
-0.01801 Tc 0.017 Tw 0 -1.2381 TD
(lowing day did not reveal any significant disease. Follow-)Tj
-0.01579 Tc T*
(up)Tj
-0.01601 Tc 0.01601 Tw 1.21832 -0.00001 Td
[(QT)70 (c measurements 1, 5, and 14 days after aripiprazole)]TJ
-0.008 Tc 0.008 Tw -1.21832 -1.23809 Td
(discontinuation were 537, 472, and 450 milliseconds, re-)Tj
-0.01601 Tc 0.01601 Tw T*
[(spectively)65 (. There were no ECG data prior to this hospital-)]TJ
-0.013 Tc 0.013 Tw T*
(ization for analysis and no documentation of a congenital)Tj
-0.01401 Tc 0.01401 Tw 0 -1.23809 TD
(long QT syndrome. After evaluation of the case using the)Tj
0 Tc 0.004 Tw 0 -1.2381 TD
(Naranjo probability scale,)Tj
ET
BT
/T1_1 1 Tf
0.002 Tc 0 Tw 6 0 0 6 417.8164 625.3132 Tm
(39)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.004 Tw 10.5 0 0 10.5 426.4782 622.0132 Tm
[(it was deter)-25 (mined that there)]TJ
-0.01601 Tc 0.01601 Tw -11.1884 -1.2381 Td
(was a probable relationship between the onset of TdP and)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(aripiprazole therapy in this patient. )Tj
ET
BT
/T1_2 1 Tf
0 Tw 10.5 0 0 10.5 309 568.2131 Tm
(Discussion )Tj
ET
BT
/T1_0 1 Tf
-0.009 Tc 0.009 Tw 10.5 0 0 10.5 319.5 547.4132 Tm
(Aripiprazole is an antipsychotic with partial dopamine)Tj
-0.015 Tc 0.015 Tw -1 -1.21906 Td
[(agonist properties that may have positive ef)20 (fects on atten-)]TJ
-0.02499 Tc 0.022 Tw 0 -1.21904 TD
(tion, concentration, and sleep-wake cycle reversal in deliri-)Tj
-0.015 Tc 0 Tw 0 -1.21905 TD
(um.)Tj
ET
BT
/T1_1 1 Tf
0 Tc 6 0 0 6 324.582 512.3132 Tm
(7)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 330.1193 509.0131 Tm
(It has been proposed that these properties may make)Tj
-0.01601 Tc 0.01601 Tw -2.01136 -1.21905 Td
(aripiprazole an ideal agent in hypoactive delirium, a com)Tj
0 Tc 22.00047 0.00001 Td
(-)Tj
0.08501 Tw -22.00047 -1.21906 Td
[(monly underdiagnosed for)-25 (m of ICU delirium.)]TJ
ET
BT
/T1_1 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 505.5812 486.7132 Tm
(7,40)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 519.5979 483.4131 Tm
(Other)Tj
-0.01401 Tc 0.013 Tw -20.05694 -1.21905 Td
(properties of aripiprazole include minimal antagonism on)Tj
-0.007 Tc 0.007 Tw T*
(muscarinic, histaminic, and )Tj
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 10.5 0 0 10.5 425.1941 457.8131 Tm
(a)Tj
ET
BT
/T1_1 1 Tf
6 0 0 6 431.7424 455.8331 Tm
(1)Tj
ET
BT
/T1_0 1 Tf
-0.007 Tc 0.007 Tw 10.5 0 0 10.5 437.3241 457.8131 Tm
[(adrener)20 (gic receptors. Ari-)]TJ
-0.02499 Tc 0.015 Tw -12.22134 -1.21905 Td
(piprazole also has lower incidences of drug-induced move)Tj
0 Tc 22.00057 0 Td
(-)Tj
0.075 Tw -22.00057 -1.21905 Td
(ment disorders and neuroleptic malignant syndrome as)Tj
-0.01401 Tc 0.01401 Tw T*
(compared with haloperidol.)Tj
ET
BT
/T1_1 1 Tf
-0.01151 Tc 0 Tw 6 0 0 6 421.3359 422.7131 Tm
(41)Tj
ET
BT
/T1_0 1 Tf
-0.01401 Tc 0.01401 Tw 10.5 0 0 10.5 429.7984 419.4131 Tm
[(Additionally)65 (, aripiprazole is)]TJ
-0.006 Tc 0.006 Tw -11.50461 -1.21905 Td
(available as an intramuscular injection, an orally disinte)Tj
0 Tc 22.00048 0 Td
(-)Tj
-0.015 Tc 0.015 Tw -22.00048 -1.21905 Td
(grating tablet, a tablet, and a liquid, allowing for adminis-)Tj
0 Tc 0.03 Tw T*
(tration when barriers to drug delivery may be present.)Tj
ET
BT
/T1_1 1 Tf
0.002 Tc 0 Tw 6 0 0 6 537.4996 384.3131 Tm
(42)Tj
ET
BT
/T1_0 1 Tf
-0.017 Tc 0.01601 Tw 10.5 0 0 10.5 309 368.2131 Tm
(Despite these properties, there is a lack of data supporting)Tj
0 Tc 0 Tw T*
(ef)Tj
0.088 Tw 0.75659 0 Td
(ficacy and safety of aripiprazole for the treatment of)Tj
-0.02499 Tc 0 Tw -0.75659 -1.21905 Td
(delirium. )Tj
-0.01401 Tc 0.01401 Tw 1 -1.2381 Td
[(No data regarding the ef)20 (fect of aripiprazole on the QT)70 (c)]TJ
-0.017 Tc 0.017 Tw -1 -1.23809 Td
[(interval in ICU populations exist. A)73.9 (vailable cardiac safety)]TJ
-0.004 Tc 0.004 Tw 0 -1.2381 TD
(data may be extrapolated from psychiatric clinical trials,)Tj
-0.021 Tc 0.021 Tw T*
(non-ICU delirium trials, and overdose reports, which have)Tj
-0.02499 Tc 0.01401 Tw 0 -1.23809 TD
[(shown aripiprazole to have a minimal ef)20 (fect on the QT)70 (c in-)]TJ
0 Tc 0.009 Tw 0 -1.2381 TD
(terval, with no reported cases of TdP)Tj
-0.00011 Tc 14.68909 0.00001 Td
(.)Tj
0 Tc 0.50906 0 Td
(In fact, some data)Tj
-0.02499 Tc 0.022 Tw -15.19816 -1.2381 Td
[(suggest that QT)70 (c interval shortening may occur)55 (. In a recent)]TJ
-0.01801 Tc 0 Tw 0 -1.23809 TD
(letter)Tj
-0.0179 Tc 1.90694 0.00001 Td
(,)Tj
-0.01801 Tc 0.01801 Tw 0.48198 0 Td
[(Muzyk et al. retrospectively evaluated the ef)17.3 (fects of)]TJ
-0.02499 Tc 0.024 Tw -2.38892 -1.2381 Td
[(intramuscular aripiprazole administration on the QT)70 (c inter-)]TJ
-0.004 Tc 0.004 Tw 0 -1.2381 TD
(val in medically ill patients.)Tj
ET
BT
/T1_1 1 Tf
-0.002 Tc 0 Tw 6 0 0 6 424.8551 215.9131 Tm
(43)Tj
ET
BT
/T1_0 1 Tf
-0.004 Tc 0.004 Tw 10.5 0 0 10.5 433.4329 212.6131 Tm
(Intramuscular aripiprazole)Tj
-0.009 Tc 0.009 Tw -11.85075 -1.23809 Td
(\(mean dose 9.64 )Tj
0 Tc [0.3 (\261)]TJ
-0.009 Tc 7.5046 0.00002 Td
(1.96 mg\) was administered to 14 men)Tj
-0.02499 Tc 0.019 Tw -7.5046 -1.23811 Td
[(and 7 women \(mean age 61.1 \261)-228 (14.5 years\), 86% of whom)]TJ
0 Tc 0.063 Tw T*
[(were on concomitant medications known to cause QT)70 (c)]TJ
-0.02299 Tc 0.02299 Tw 0 -1.23809 TD
[(prolongation. The reported change of the QT)70 (c interval was)]TJ
0 Tc 0 Tw 0 -1.2381 TD
(2.1 )Tj
0.02699 Tw 1.52693 0.00001 Td
[(\261)-262 (7.3 milliseconds from a mean baseline of 479.8 \261)]TJ
-0.011 Tc 0.011 Tw -1.52693 -1.2381 Td
[(46.2 milliseconds \(p = 0.39\). T)70 (en of the 21 patients had a)]TJ
-0.02499 Tc 0.015 Tw 0 -1.23809 TD
(decrease in QT)Tj
-0.0251 Tc 5.66121 0.00001 Td
(c)Tj
-0.02499 Tc 0.65869 0 Td
(interval \(range 10)Tj
0 Tc 6.76195 0.00001 Td
(-)Tj
-0.02499 Tc [0.3 (32 milliseconds\). How)]TJ
0 Tc 8.91872 0.00002 Td
(-)Tj
-0.024 Tc 0.024 Tw -22.00057 -1.23812 Td
[(ever)40 (, 6 patients had an increase of greater than 30 millisec-)]TJ
-0.02499 Tc 0.019 Tw 0 -1.2381 TD
[(onds from baseline \(range 30)-75 (-)-25 (82 milliseconds\). Discussion)]TJ
-0.02299 Tc 0.022 Tw 0 -1.23809 TD
[(regarding patients with lar)5.7 (ge increases in QT)]TJ
-0.02251 Tc 17.02749 0.00002 Td
(c)Tj
-0.02299 Tc 0.67136 0 Td
(interval was)Tj
-0.024 Tc 0.024 Tw -17.69884 -1.23811 Td
[(not provided, making it dif)20 (ficult to estimate the probability)]TJ
-0.021 Tc 0.021 Tw 0 -1.2381 TD
(that aripiprazole was responsible. Limitations of this study)Tj
-0.01199 Tc 0.01199 Tw 0 -1.23809 TD
(consist of the small number of patients, and while the au-)Tj
ET
0 0 0 0 k
50.5 14 378.5 14.524 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.02299 Tc 0 Tw 10 0 0 10 50.5 21.6856 Tm
[(e1)57 (1)]TJ
ET
BT
/T1_4 1 Tf
0 Tc 5 0 0 5 73.1366 23.1856 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 86.3177 21.6856 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 219.4427 23.1856 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 232.6237 21.6856 Tm
[(2013 February)55 (, V)110 (olume 47)]TJ
ET
0 0 0 0 k
463 17.694 80.5 10.806 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tw 10 0 0 10 488.4582 21.6616 Tm
(theannals.com)Tj
ET
0 0 0 0 k
50.5 740.1929 234 10 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.0251 Tc 8 0 0 8 50.5 744.7228 Tm
(S)Tj
-0.02499 Tc 0.013 Tw 0.76835 0 Td
(Nelson, JG Leung)Tj
ET
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 284.35733 11 Tm
( at UNIV CALGARY LIBRARY on May 25, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
52 0 obj
<</BaseFont/YGSLBL+Symbol/Encoding 49 0 R/FirstChar 32/FontDescriptor 51 0 R/LastChar 97/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 631]>>
endobj
49 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 97/alpha]/Type/Encoding>>
endobj
51 0 obj
<</Ascent 921/CapHeight 671/Descent -223/Flags 4/FontBBox[-180 -292 1090 1005]/FontFile3 50 0 R/FontName/YGSLBL+Symbol/ItalicAngle 0/StemH 0/StemV 41/Type/FontDescriptor/XHeight 684>>
endobj
50 0 obj
<</Length 446/Length1 446/Subtype/Type1C>>stream
  YGSLBL+Symbol   Fø øøøø)ÁûHû¸úÖú
 ‹‹
 ‹‹   ú   ö   ÿª  Ÿ „‹alpha002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Simpele is a trademark of Stream Technologies Inc.Simpele     ‡ šü$xy®kÓø'³}w³ñXøÿ÷xU„ypljp´Ô{÷÷Ï3LûDˆø÷tPÊ*VWt\_`_xI.û*Ù,÷³À›¡­« ¥¨Åx&¯§d¯ª®ººûh÷%m:ø=n\[]qt™§us«|ÏÜ÷¸æÌ¶¹oešnNms£ø†÷?˜÷‹ûv¯
´
_÷ù
endstream
endobj
72 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
73 0 obj
<</OP false/OPM 0/op false>>
endobj
86 0 obj
<</A 87 0 R/Border[0 0 0]/Rect[243.612 9.0 285.357 16.0]/Subtype/Link/Type/Annot>>
endobj
87 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
65 0 obj
[88 0 R]
endobj
66 0 obj
<</Length 11656>>stream
1 g
/GS0 gs
0 783 0 0 re
f
0 0 0 0 k
/GS1 gs
51.528 32.7739 492 498.167 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
27.357 0 0 27.357 50.1452 510.7603 Tm
(H)Tj
ET
BT
/T1_1 1 Tf
0.283 Tw 10.5 0 0 10.5 69.778 523.7603 Tm
(aloperidol, a first-generation an-)Tj
-0.02 Tc 0.02 Tw 0 -1.2381 TD
(tipsychotic, has been considered the)Tj
-0.01401 Tc 0.01401 Tw -1.7381 -1.2381 Td
(gold standard for the treatment of inten-)Tj
-0.006 Tc 0.006 Tw 0 -1.23809 TD
(sive care unit \(ICU\) delirium.)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 174.3467 488.0604 Tm
(1)Tj
ET
BT
/T1_1 1 Tf
-0.006 Tc 0.006 Tw 10.5 0 0 10.5 179.9351 484.7603 Tm
(In an at-)Tj
0 Tc 0.088 Tw -12.22925 -1.2381 Td
[(tempt to use ef)22.3 (fective, and potentially)]TJ
-0.02299 Tc 0.022 Tw T*
(safer agents, clinicians have increasingly)Tj
0 Tc 0.71001 Tw T*
[(ordered second-generation antipsy)3 (-)]TJ
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
(chotics \(SGAs\) for managing ICU deliri)Tj
0 Tc 15.19104 0 Td
(-)Tj
-0.01601 Tc 0.01601 Tw -15.19104 -1.2381 Td
[(um. However)40 (, only olanzapine, quetiap-)]TJ
0 Tc 0.017 Tw 0 -1.23809 TD
(ine, and ziprasidone have been studied)Tj
0.00999 Tw T*
[(for ICU delirium in a prospective, ran)4.9 (-)]TJ
0.32899 Tw 0 -1.2381 TD
[(domized controlled manner)55 (.)]TJ
ET
BT
/T1_2 1 Tf
0 Tw 6 0 0 6 175.946 384.0604 Tm
[(2)-25.9 (-)-75.7 (4)]TJ
ET
BT
/T1_1 1 Tf
10.5 0 0 10.5 190.626 380.7603 Tm
(Other)Tj
-0.02499 Tc 0.011 Tw -13.24743 -1.23809 Td
(SGAs with literature supporting their use)Tj
0 Tc 0.202 Tw 0 -1.23809 TD
(for delirium include aripiprazole and)Tj
-0.02299 Tc 0.02299 Tw 0 -1.2381 TD
[(risperidone. However)40 (, these data involve)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(only non-ICU populations.)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 158.0873 332.0604 Tm
[(5)-25 (-17)]TJ
ET
BT
/T1_1 1 Tf
0 Tc 10.5 0 0 10.5 62.028 315.7603 Tm
(Antips)Tj
-0.015 Tc 0.13499 Tw 2.6665 0.00001 Td
(ychotics pri)Tj
0 Tc 4.64745 0 Td
(marily exert their)Tj
0.13901 Tw -8.31395 -1.2381 Td
(action through dopamine antagonism.)Tj
0.061 Tw T*
[(Examples of adverse ef)20 (fects related to)]TJ
0.16701 Tw 0 -1.2381 TD
(this mechanism include drug-induced)Tj
-0.02499 Tc 0.017 Tw 0 -1.23809 TD
(movement disorders and neuroleptic ma-)Tj
0 Tc 0.13901 Tw 0 -1.2381 TD
(lignant syndrome. These types of ad-)Tj
-0.00999 Tc 0.00999 Tw T*
(verse events are less likely to be caused)Tj
-0.007 Tc 0.007 Tw 0 -1.23809 TD
(by SGAs than by haloperidol.)Tj
ET
BT
/T1_2 1 Tf
-0.005 Tc 0 Tw 6 0 0 6 174.9286 228.0604 Tm
(18)Tj
ET
BT
/T1_1 1 Tf
-0.007 Tc 10.5 0 0 10.5 183.4727 224.7603 Tm
(Proper)Tj
0 Tc 2.62482 0.00001 Td
(-)Tj
-0.02499 Tc 0.015 Tw -15.19098 -1.2381 Td
(ties of SGAs that may account for a low)Tj
0 Tc 15.19103 0.00001 Td
(-)Tj
0.09399 Tw -15.19103 -1.2381 Td
[(er adverse ef)20 (fect burden include sero-)]TJ
0.13699 Tw T*
(tonin 5)Tj
0 Tw 2.96713 0.00001 Td
(-HT)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 6 0 0 6 100.1709 183.7802 Tm
(2A)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0.13699 Tw 10.5 0 0 10.5 111.5614 185.7603 Tm
(antagonism, faster dissociation from the)Tj
-0.015 Tc 0.015 Tw -5.71747 -1.2381 Td
(dopamine D)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 101.7506 170.7802 Tm
(2)Tj
ET
BT
/T1_1 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 107.2875 172.7603 Tm
[(receptor)40 (, and/or lower D)]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 206.819 170.7802 Tm
(2)Tj
ET
BT
/T1_1 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 212.3558 172.7603 Tm
(receptor occupan-)Tj
-0.02499 Tc 0 Tw -15.31693 -1.2381 Td
[(cy)65 (.)]TJ
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 62.5914 163.0604 Tm
(19,20)Tj
ET
BT
/T1_1 1 Tf
-0.00999 Tc 0.009 Tw 10.5 0 0 10.5 62.028 146.7603 Tm
[(An additional adverse ef)20 (fect of many antipsychotics is)]TJ
-0.01401 Tc 0.01401 Tw -1 -1.2381 Td
[(prolongation of the corrected QT \(QT)70 (c\) interval. A medi-)]TJ
-0.02299 Tc 0.02299 Tw 24.57143 4.99637 Td
[(cation\325)55 (s ability to cause QT)70 (c interval prolongation is likely)]TJ
-0.02499 Tc 0.004 Tw 0 -1.2381 TD
(related to the degree to which it blocks the delayed rectifier)Tj
-0.02299 Tc 0.02299 Tw 0 -1.23809 TD
(potassium channel, which is responsible for ventricular re-)Tj
-0.02499 Tc 0 Tw 0 -1.2381 TD
(polarization.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 6 0 0 6 358.8845 150.5222 Tm
(21)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.007 Tw 10.5 0 0 10.5 367.0255 147.2222 Tm
(Delays in ventricular repolarization manifest)Tj
-0.02299 Tc 0.02299 Tw -5.47595 -1.2381 Td
[(as longer QT)70 (c intervals, a surrogate marker for torsades de)]TJ
-0.019 Tc 0.019 Tw 0 -1.23809 TD
(pointes \(TdP\).)Tj
ET
BT
/T1_2 1 Tf
-0.017 Tc 0 Tw 6 0 0 6 366.972 124.5223 Tm
(22)Tj
ET
BT
/T1_1 1 Tf
-0.019 Tc 0.019 Tw 10.5 0 0 10.5 375.3664 121.2222 Tm
(TdP is a polymorphic ventricular arrhyth)Tj
0 Tc 15.68256 0.00001 Td
(-)Tj
-0.02 Tc 0.02 Tw -21.95288 -1.2381 Td
(mia that may present as lightheadedness and syncope, and)Tj
0 Tc 0.019 Tw 0 -1.2381 TD
(in rare cases, can be fatal.)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 0 Tw 6 0 0 6 418.6405 98.5222 Tm
(23)Tj
ET
BT
/T1_1 1 Tf
-0.00011 Tc 10.5 0 0 10.5 427.462 95.2222 Tm
(A)Tj
0 Tc 0.019 Tw 0.99051 0 Td
[(QT)70 (c interval greater than)]TJ
-0.02499 Tc 0.011 Tw -12.22231 -1.23809 Td
(450 milliseconds for men and 470 milliseconds for women)Tj
0.021 Tw T*
[(indicates prolongation, with QT)70 (c intervals greater than 500)]TJ
0 Tc 0.03 Tw 0 -1.23809 TD
(milliseconds or a change from baseline that exceeds 60)Tj
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
(milliseconds being considered clinically significant.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 514.5276 46.5223 Tm
(24)Tj
ET
0 0 0 0 k
51.528 580 492 85 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.03999 Tc 0.011 Tw 16.8 0 0 16 51.528 636.1398 Tm
[(T)165 (orsades de P)75 (ointes After Administration of Lo)34 (w-Dose Aripipraz)20 (ole)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 10.5 0 0 10 51.528 600.1398 Tm
(Sarah Nelson, Jonathan G Leung)Tj
ET
0 0 0 0 k
148.528 15.25 395 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0.013 Tw 10 0 0 10 260.1243 21.4116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 393.2493 22.9116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 406.4304 21.4116 Tm
[(2013 February)55 (, V)110 (olume 47    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 516.9602 22.9116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 10 0 0 10 530.1413 21.4116 Tm
[(e1)57 (1)]TJ
ET
0 0 0 0 k
51.028 15 79.5 13.5 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.02499 Tc 10 0 0 10 51.028 21.6616 Tm
(theannals.com)Tj
ET
0 0 0 0.14999 k
230.528 209.403 313 321.538 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.024 Tc 7 0 0 7 242.528 510.5835 Tm
(OBJECTIVE)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 280.6865 510.5835 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8.5 0 0 8.5 286.2077 510.5835 Tm
[(T)111 (o describe a case of torsades de pointes \(TdP\) in a patient treated)]TJ
-0.02499 Tc 0.011 Tw -5.13879 -1.26471 Td
(with aripiprazole.)Tj
ET
BT
/T1_6 1 Tf
-0.00011 Tc 0 Tw 7 0 0 7 242.528 486.0835 Tm
(C)Tj
0 Tc [-0.1 (ASE)-421 (SUMMAR)36 (Y)]TJ
ET
BT
/T1_6 1 Tf
10 0 0 10 300.3037 486.0835 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.017 Tw 8.5 0 0 8.5 306.1387 486.0835 Tm
[(A)-295 (42-year-old white male with schizophrenia, diabetes, hyper-)]TJ
-0.02499 Tc 0.009 Tw -7.48361 -1.2647 Td
(tension, and a history of stroke was admitted to the intensive care unit\ following 2)Tj
-0.017 Tc 0.002 Tw 0 -1.2647 TD
[(days of fever)55 (, diarrhea, and altered mental status. Following the resolution of his)]TJ
-0.015 Tc 0.132 Tw 0 -1.26471 TD
(acute illness, previous therapy with quetiapine 400 mg orally at bedtime\ was)Tj
-0.022 Tc 0.007 Tw 0 -1.2647 TD
(resumed for schizophrenia and presumed delirium. Quetiapine was disconti\nued)Tj
-0.024 Tc 0.009 Tw T*
(after 1 dose because of QT)Tj
-0.0242 Tc 11.42332 0 Td
(c)Tj
-0.024 Tc 0.73868 0 Td
[(interval prolongation. T)59.5 (wenty-three days later)]TJ
-0.0242 Tc 18.82122 0 Td
(,)Tj
-0.024 Tc 0.51663 0 Td
(with a)Tj
-0.034 Tc 0.019 Tw -31.49985 -1.26472 Td
[(baseline QT)111 (c interval of 414 milliseconds, aripiprazole 2.5 mg orally once daily wa\s)]TJ
-0.024 Tc 0.009 Tw T*
[(initiated. Following 5 days of aripiprazole therapy)74 (, the patient had a cardiac arrest)]TJ
-0.03999 Tc 0.019 Tw T*
[(due to TdP)129 (. Normal sinus rhythm was restored after 30 seconds of cardiopulmonary)]TJ
-0.01601 Tc 0.00101 Tw T*
(resuscitation, 1 shock of 200 Joules, and 4 g of intravenous magnesium s\ulfate.)Tj
-0.015 Tc 0.11099 Tw 0 -1.26471 TD
(Serial electrocardiographs obtained after aripiprazole discontinuation r\evealed)Tj
-0.03999 Tc 0.011 Tw 0 -1.2647 TD
(resolution of QT)Tj
-0.0401 Tc 6.38341 0 Td
(c)Tj
-0.03999 Tc 0.70887 0 Td
(interval prolongation. )Tj
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 7 0 0 7 242.528 354.0835 Tm
(DISCUSSION)Tj
ET
BT
/T1_6 1 Tf
10 0 0 10 286.083 354.0835 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
0.12199 Tw 8.5 0 0 8.5 292.8121 354.0835 Tm
(Aripiprazole is a second-generation antipsychotic that may be)Tj
-0.01601 Tc 0.01601 Tw -5.91578 -1.2647 Td
[(selected for patients with prolonged QT)111 (c intervals and at risk for TdP)128 (. Data from)]TJ
-0.019 Tc 0.019 Tw T*
[(trials indicate that aripiprazole has minimal ef)18 (fects on the QT)110 (c interval. However)55 (,)]TJ
-0.01199 Tc 0.01199 Tw T*
(in this case, aripiprazole was associated with TdP in a patient with min\imal risk)Tj
0 Tc 0.216 Tw 0 -1.26471 TD
(factors. The Naranjo probability scale was used to determine a probable)Tj
-0.02499 Tc 0.004 Tw 0 -1.2647 TD
(association between aripiprazole and the development of TdP)Tj
-0.02521 Tc 25.76781 0 Td
(.)Tj
-0.02499 Tc 0.50993 0 Td
[(T)111 (o our knowledge,)]TJ
0.011 Tw -26.27774 -1.26471 Td
(this is the first reported case of TdP associated with the use of aripip\razole.)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tc 0 Tw 7 0 0 7 242.528 275.8335 Tm
(CONCLUSIONS)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 293.1843 275.8335 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
-0.00999 Tc 0.00999 Tw 8.5 0 0 8.5 298.7772 275.8335 Tm
(Five days of low-dose aripiprazole therapy was associated with)Tj
-0.01601 Tc 0.01601 Tw -6.61755 -1.26471 Td
(the development of TdP in a man with minimal risk factors. Clinicians sh\ould be)Tj
-0.02499 Tc 0.011 Tw 0 -1.26471 TD
(aware of this potential adverse drug event with aripiprazole.)Tj
ET
BT
/T1_7 1 Tf
8.5 0 1.80673 8.5 242.528 239.3335 Tm
(Ann Pharmacother)Tj
ET
BT
/T1_0 1 Tf
0 Tw 8.5 0 0 8.5 314.109 239.3335 Tm
[(2013;47:e1)74 (1.)]TJ
0.011 Tw -8.4213 -1.76471 Td
(Published Online, 29 Jan 2013, )Tj
ET
BT
/T1_7 1 Tf
0 Tw 8.5 0 1.80673 8.5 356.8733 224.3335 Tm
(theannals.com)Tj
ET
BT
/T1_0 1 Tf
-0.0251 Tc 8.5 0 0 8.5 409.3752 224.3335 Tm
(,)Tj
-0.02499 Tc 0.011 Tw 0.51687 0 Td
(doi: 10.1345/aph.1R387)Tj
ET
0 0 0 1 K
2 w 
217.088 705.426 m
364.884 705.426 l
S
BT
/T1_8 1 Tf
0.075 Tc 18 0 0 18 230.1894 708.0727 Tm
[(C)-25 (ASE REPOR)90 (TS)]TJ
ET
1.472 704.329 223.001 16.046 re
f
0.5 w 
51.944 108.7499 m
287 108.7499 l
S
BT
/T1_0 1 Tf
-0.02499 Tc 8.5 0 0 8.5 51.944 96.4997 Tm
(Author information provided at end of text.)Tj
0 -1.8235 TD
[(\251)-264 (1967-2013 Harvey Whitney Books Co. All rights reserved. No)]TJ
0 -1.1176 TD
(part of this document may be reproduced or transmitted in any)Tj
T*
(form or by any means without prior written permission of Harvey)Tj
0 -1.1177 TD
(Whitney Books Co. For reprints of any article appearing in )Tj
ET
BT
/T1_7 1 Tf
0 Tw 8.5 0 1.80673 8.5 260.435 52.4996 Tm
(The)Tj
-24.2908 -1.1176 Td
(Annals)Tj
ET
BT
/T1_0 1 Tf
-0.0251 Tc 8.5 0 0 8.5 76.6504 42.9997 Tm
(,)Tj
-0.02499 Tc 0.011 Tw 0.5169 0 Td
(please contact 415sales@hwbooks.com)Tj
1 g
/T1_9 1 Tf
-0.278 Tc 0 Tw 1 0 0 1 -1000 1783 Tm
( )Tj
ET
BT
0 g
/GS2 gs
/T1_10 1 Tf
0 Tc 5 0 0 5 284.35733 11 Tm
( at UNIV CALGARY LIBRARY on May 25, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
24 0 obj
<</BaseFont/AXVMOU+GillSans-Bold/Encoding 21 0 R/FirstChar 32/FontDescriptor 23 0 R/LastChar 122/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 781 0 0 802 0 0 0 0 0 0 0 615 0 0 0 656 0 0 0 719 0 0 0 0 0 0 0 0 0 0 0 0 531 0 0 583 552 302 0 0 271 0 0 271 958 583 594 583 0 448 427 406 0 0 781 0 0 521]>>
endobj
44 0 obj
<</BaseFont/RQAHXW+GillSans/Encoding 41 0 R/FirstChar 32/FontDescriptor 43 0 R/LastChar 84/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 708 0 500 0 0 0 0 0 0 0 0 0 823 510 0 604 458 604]>>
endobj
48 0 obj
<</BaseFont/WQZJWI+Helvetica/Encoding 45 0 R/FirstChar 32/FontDescriptor 47 0 R/LastChar 32/Subtype/Type1/Type/Font/Widths[278]>>
endobj
45 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space]/Type/Encoding>>
endobj
47 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 34/FontBBox[-166 -224 1000 931]/FontFile3 46 0 R/FontName/WQZJWI+Helvetica/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
46 0 obj
<</Length 288/Length1 288/Subtype/Type1C>>stream
  WQZJWI+Helvetica   @ø øøøøû:ûtú|ú7
 ‹‹
 ‹‹   ò   ï   õ¬   ÿ €ˆ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki      üu¡øŸš÷)›™Ÿ÷¡–ü}š×
ã
_÷ªù
endstream
endobj
41 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 65/A 67/C 69/E 79/O/P 82/R/S/T]/Type/Encoding>>
endobj
43 0 obj
<</Ascent 716/CapHeight 682/Descent -230/Flags 32/FontBBox[-162 -230 1041 911]/FontFile3 42 0 R/FontName/RQAHXW+GillSans/ItalicAngle 0/StemH 0/StemV 89/Type/FontDescriptor/XHeight 728>>
endobj
42 0 obj
<</Length 850/Length1 850/Subtype/Type1C>>stream
  RQAHXW+GillSans   @ø øøøøû6ûzú¥ú#
 ‹‹
 ‹‹   î   ê  ·  & |…Copyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corpration Plc.Gill Sans    $ " 4 &  3 1 0 5 
   M „ Ø\˜ïüÅ‚åøœå»ğù$ù².DœEûmû1û,ûdû#÷ûY÷”öÔ¤®ÎöY>7p>û8ûõ÷-÷*÷÷÷0ÚÓuZßœ v÷]ãø!w‹ù/÷şùBFû¹ıBïá÷]÷¶æû]ïûéø¬÷û‹ûhûT‚ãø ã³æ÷`æø#ù«[W›Wû9DûûO÷»{‹û!eh[?HL®ËYû`ÄÇwÕ÷ÜÙö÷mû»‰‹÷»¸¬Ê¹Ã{TÅû*‹ã÷hã÷bãÖíøbù>üı>ø ãû¾÷h÷«ãû«÷b÷µü] v÷¼ã÷jßØí÷YğØù>ı>í÷¼´½´{û ååû ÷	\Ìz¢nºWàeÊM´Ô¨´Æ‹Ú‹÷
5Ôû‹A7Êê±dKŒRŒmU"Lû  v÷»ã÷gãÑí÷{ğÑù>ı>í÷»ñ÷2Óßö÷ Gãû)û3÷ä¦UYG\dBû÷A‚åøœå¸ğø§ğ¸÷éûM÷!û9÷s÷{÷÷:÷L÷Rû"÷4ûuûqû%û5ûQğ÷*÷÷÷,÷-÷ûû*û)ûûû-û,û÷÷)] vøæã÷‘íøßù>üÎ3÷€üæíøæ÷€•ù>—û‰”÷–—÷ÛüÆ‹Û
äZ 

yXO	÷ªù
endstream
endobj
21 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 45/hyphen 65/A 68/D 76/L 80/P 84/T 97/a 100/d/e/f 105/i 108/l/m/n/o/p 114/r/s/t 119/w 122/z]/Type/Encoding>>
endobj
23 0 obj
<</Ascent 716/CapHeight 682/Descent -221/Flags 262176/FontBBox[-177 -230 1167 929]/FontFile3 22 0 R/FontName/AXVMOU+GillSans-Bold/ItalicAngle 0/StemH 0/StemV 145/Type/FontDescriptor/XHeight 728>>
endobj
22 0 obj
<</Length 1769/Length1 1769/Subtype/Type1C>>stream
  AXVMOU+GillSans-Bold   Aø øøøøûEûzú5
 ‹‹
 ‹‹       1±  Ã }‹”Copyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corporation Plc.Gill Sans BoldGill Sans    5 P S T B E F  1 J O U " G N - X  % Q [ M    & m ­ pÊ`™Û\£/j„É"G`üĞ vøÁ÷÷§÷>ùHù>ı,û÷‹üÁ÷>øÁ÷‹S‚á÷Çá°÷/÷f÷/øÁ÷z÷Eû&Êûûû9û1û%÷,÷+ñ÷1Ã÷Kû/&gSGTX®÷ó¶¼ÊÔªO1û^ v÷â÷‚wË÷%°÷eøaû%üa÷%÷[Ğà«­½À¢¤s±³÷aªr–n‹S[^+`‰ûs‚ì÷v¾á°÷ê÷øøH£[`•Qû>R6û+÷y—‹Hvp~`T\Ÿ\%€ŸÒtÕ÷ÏÁë÷.ûy‹¾«¬¨ÉdÊû‚á÷¼ì¬÷'÷÷%ø§÷si€‰|‚”¢÷fğ<²ûBHxfOû
º¹Í©ÅÊŸi`ˆûUO:uûQÂTÕ½¹™±Ãf•¢|»²Ä£³ûtÚusn~pqv¡¦¹´ŸáªH‚ì3ã÷±ì÷hw®÷'÷Y÷%¼ø ù>û%û…dd•aû/)û!ûç%÷¼±˜¬´|f÷%¼û%÷pmr€lG`Ãßç¶ÀÔ¥­| )‚á÷×ğá°÷*÷_÷ø’÷#ZG^zQ0S»İ†÷ß÷<’ûêûû"&'û!û$ô-÷6¯â‹ÈŞûÔ÷{Ë‘°°ÄÃ±eL‘ü‘ v÷¦÷÷2÷Ş÷>÷M÷CŞù>ı>÷>÷¦÷÷1Ï÷ëèE÷û0ûûÇç¬vQXoo=<ü vøawå÷4Â÷4û,÷%è÷døaû%üa÷%0BùG_gg__¯g··¯¯··g¯_H vø	ã3ìÇ÷%÷A÷%Ø÷aøaû%üa÷%¸÷½Ä±¦¯´ªpJû­÷%÷¹÷+´CP^uV]ûˆ‚ö÷œîÙ÷%øøaû<÷%yûUûloÍûZûŞ_ë¸±“ ¾ôwdo„m^q¨¸÷R÷<÷ v÷÷÷÷7‹wù›Øøoù>ûYû§ı>÷H¾÷÷ÅÃû÷Kûµ÷’ûfèï÷ûğ v÷şî÷÷‚wÜ÷%è÷vøa¨È®Ÿ¸›–Š†±Ø÷	èue‘oû	6DûtI(Íûş÷%÷şÍî÷È vø	ì‚wÊ÷%÷[÷%÷[÷%¼÷døaû%üa÷%Ü÷Éµ®±¡±¶¸r@û¥÷%÷»¾¬²¦µÀ«fIû¢÷%÷¼ô@Ğ"FVnFOÍkU«;np†€p¼qqzrth‹÷øÁw×÷>øè÷ûòøÁû>ı>øœ÷—vøjwŠù£ø÷†÷ûĞ÷cøjû(*û’%÷’3$û’*÷’û(÷düjÏûÑ v÷9÷¯÷™÷½÷¾û™û÷™÷,‹÷øD÷Ö÷>÷á÷CÖù>ı>÷®÷¤÷÷$÷X÷Oû÷/ûûû÷÷5Ê(û	'Xûû?ûHûev÷qì÷›v°é-òÄ÷%÷[÷'ö÷^øaû%ıG÷%÷‘w­·´÷åì÷(î÷-ñûYb|ib0§¯¢”ªĞ³X35_UDnq” nû‹î÷›îømµøa(÷jûûşømîû€÷€÷şü vù>wÊ÷%÷dù>û%ı>÷%‚”ù>”ûz”÷Š—÷Ù’üÆ”î
Œ
yXO	÷ªù
endstream
endobj
67 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
68 0 obj
<</OP false/OPM 0/op false>>
endobj
88 0 obj
<</A 89 0 R/Border[0 0 0]/Rect[243.612 9.0 285.357 16.0]/Subtype/Link/Type/Annot>>
endobj
89 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
63 0 obj
<</CreationDate(D:20130205160019Z)/Creator(QuarkXPress\(tm\) 6.5)/ModDate(D:20150525054051-07'00')/Producer(QuarkXPress\(tm\) 6.5)/Title(Layout 1)/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)>>
endobj
xref
0 90
0000000000 65535 f
0000034662 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000001835 00000 n
0000053329 00000 n
0000053860 00000 n
0000053657 00000 n
0000050593 00000 n
0000025632 00000 n
0000026262 00000 n
0000026057 00000 n
0000013300 00000 n
0000023639 00000 n
0000024004 00000 n
0000023797 00000 n
0000013967 00000 n
0000092618 00000 n
0000093009 00000 n
0000092797 00000 n
0000089932 00000 n
0000019188 00000 n
0000019618 00000 n
0000019410 00000 n
0000014409 00000 n
0000023095 00000 n
0000023384 00000 n
0000023181 00000 n
0000014255 00000 n
0000059221 00000 n
0000059643 00000 n
0000059430 00000 n
0000050199 00000 n
0000051495 00000 n
0000051862 00000 n
0000051651 00000 n
0000051142 00000 n
0000091371 00000 n
0000091691 00000 n
0000091489 00000 n
0000090305 00000 n
0000090716 00000 n
0000091006 00000 n
0000090803 00000 n
0000090570 00000 n
0000077122 00000 n
0000077418 00000 n
0000077218 00000 n
0000076847 00000 n
0000015274 00000 n
0000015695 00000 n
0000015480 00000 n
0000014795 00000 n
0000001871 00000 n
0000001945 00000 n
0000002263 00000 n
0000002544 00000 n
0000002837 00000 n
0000000016 00000 n
0000095115 00000 n
0000000096 00000 n
0000078199 00000 n
0000078224 00000 n
0000094857 00000 n
0000094915 00000 n
0000015185 00000 n
0000062973 00000 n
0000062998 00000 n
0000077941 00000 n
0000077999 00000 n
0000034961 00000 n
0000034986 00000 n
0000062715 00000 n
0000062773 00000 n
0000003094 00000 n
0000003119 00000 n
0000034703 00000 n
0000034761 00000 n
0000034806 00000 n
0000034905 00000 n
0000062818 00000 n
0000062917 00000 n
0000078044 00000 n
0000078143 00000 n
0000094960 00000 n
0000095059 00000 n
trailer
<</Size 90/Root 62 0 R/Info 63 0 R/ID[<E7209500DAC2DB2FD049C41E219B9410><73BE7F68D21DB2110A00640810000000>]>>
startxref
95341
%%EOF
